Medication Guide App

Epoetin Alfa

Pronunciation

Class: Hematopoietic Agents
VA Class: BL400
Chemical Name: 1-165-Erythropoietin (human clone λHEPOFL13 protein moiety)
Molecular Formula: C809H1301N229O240S5
CAS Number: 113427-24-0
Brands: Epogen, Procrit

Warning(s)

  • Risk of Increased Mortality and Serious Adverse Events
  • Increased risk of death, serious cardiovascular events, and stroke reported in patients with chronic kidney disease (CKD) receiving therapy with epoetin alfa or other erythropoiesis-stimulating agents (ESAs) targeted to hemoglobin concentrations >11 g/dL in controlled clinical studies.1 400 585 586 587 588 589 590 594 597 602 603 604 615 620 622 624 (See Increased Mortality and Cardiovascular and Thromboembolic Events under Cautions.)

  • No trial has identified a hemoglobin target, ESA dosage, or dosing strategy that does not increase these risks.1 400

  • Use lowest ESA dosage sufficient to reduce need for RBC transfusion in patients with CKD.1 400 624

  • ESA therapy shortened overall survival and increased risk of tumor progression or recurrence in some studies in patients with breast, non-small cell lung, head and neck, lymphoid, or cervical cancers.1 400 589 590 597 599 600 602 603 604 605 606 (See Increased Mortality and/or Tumor Progression under Cautions.)

  • To decrease these risks and risk of serious cardiovascular and thromboembolic events in anemic patients with cancer, use lowest ESA dosage sufficient to avoid RBC transfusion.1 400 585 586 587 588 589 590 597

  • Epoetin alfa may be prescribed and/or dispensed to cancer patients only by clinicians and institutions enrolled in the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) Oncology program.1 619 621 (See Restricted Distribution Program in Oncology under Dosage and Administration.)

  • Use ESAs in cancer patients only for treatment of anemia caused by concomitant myelosuppressive chemotherapy.1 400 589 590 597 602 603 604 605

  • ESAs not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.1 400 597 608

  • Discontinue ESAs following completion of a course of chemotherapy.1 400 597

  • Due to increased risk of DVT, DVT prophylaxis recommended in surgical patients receiving epoetin alfa perioperatively.1 400 589 590 602 604

REMS:

FDA approved a REMS for epoetin alfa to ensure that the benefits outweigh the risks. The REMS may apply to one or more preparations of epoetin alfa and consists of the following: medication guide, elements to assure safe use, communication plan, and implementation system. See the FDA REMS page () or the ASHP REMS Resource Center (). Also see Restricted Distribution Program in Oncology under Dosage and Administration.

Introduction

Biosynthetic (recombinant DNA origin) form of the glycoprotein hormone erythropoietin, a hematopoietic agent that principally affects erythropoiesis.1 2 3 4 5 7 8 10 11 13 14 18 19 21 23 25 32 33 34 37 43 51 52 53 54 55 58 70 71 72 120 121 122 159 164 166 169 174 187 206 222 236 246 255 305 336 346 366 399 400 405 408 414 418 453 464

Uses for Epoetin Alfa

Anemia of Chronic Kidney Disease

Treatment of anemia associated with chronic kidney disease (CKD) to reduce need for RBC transfusions; designated an orphan drug by FDA for this use.1 3 4 5 11 22 23 32 50 51 52 53 59 65 66 68 70 76 77 119 122 159 165 173 283 312 322 324 336 366 371 400 410 414 519

First-line therapy for appropriately selected patients with anemia of CKD.2 51 453 510 565 601

Used to increase and/or maintain hemoglobin concentrations and hematocrit and decrease the need for RBC transfusions.1 3 4 5 11 22 23 32 66 70 119 173 303 324 366 400 410

Used in CKD patients who currently are undergoing dialysis therapy, as well as predialysis patients with CKD and severe symptoms of anemia who do not yet require maintenance dialysis.1 3 4 5 11 22 23 32 50 51 52 53 59 65 66 68 70 76 77 119 122 159 165 173 283 312 322 324 336 366 371 400 410 414 Manufacturers and some authorities recommend use in patients with end-stage kidney disease who currently are undergoing hemodialysis or peritoneal dialysis therapy and also in predialysis patients with CKD who have a hematocrit <30% or hemoglobin concentration <10 g/dL.1 6 11 34 66 112 119 173 247 278 298 312 322 324 400 410 601

Some evidence suggests once-weekly darbepoetin alfa has similar safety and efficacy as equivalent doses of epoetin alfa given 2 or 3 times weekly in patients with CKD undergoing hemodialysis or peritoneal dialysis.573 574 575 576 577 578 579 580

Slideshow: 2013 Drug News Round-Up: Top 20 Stories

ESAs, including epoetin alfa, may increase risk for death, stroke, and serious cardiovascular events when targeted to hemoglobin concentrations >11 g/dL in patients with CKD.1 114 166 187 261 336 400 518 584 585 586 587 594 610 615 620 622 624 625 (See Boxed Warning.) FDA has issued public health advisories regarding these risks.584 585 586 587 588 589 590 602 603 604 624 Weigh potential benefits of ESAs in reducing RBC transfusions against risk of serious cardiovascular events in patients with CKD.1 400 624 Individualize therapy and use lowest possible dosage that will reduce need for RBC transfusion.1 400 624

Not intended for patients with CKD who require acute correction of severe anemia; do not use as a substitute for emergency transfusion.1 366 400

Not established that ESAs improve quality of life, fatigue, or patient well-being.1 400

Zidovudine-induced Anemia in HIV-infected Patients

Treatment of anemia associated with zidovudine therapy in patients with HIV infection; indicated in patients with endogenous serum erythropoietin concentrations ≤500 milliunits/mL and who are receiving zidovudine dosages of ≤4.2 g per week (designated an orphan drug by FDA for this use).1 2 122 124 187 199 286 293 294 335 400 429 444 452 478 519 554 1 2 122 124 187 199 286 293 294 335 400 429 444 452 554

Used to increase and/or maintain hemoglobin concentrations and hematocrit and decrease the need for transfusions.1 2 122 124 187 199 286 293 294 335 400 429 444 452 554

Has been used to treat anemia associated with HIV infection in patients not receiving zidovudine.452 523

Not intended for patients who require acute correction of severe anemia; do not use as a substitute for emergency transfusion.1 400

Not established that ESAs improve quality of life, fatigue, or patient well-being.1 400

Chemotherapy-induced Anemia in Patients with Nonmyeloid Malignancies

Treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies in whom chemotherapy is planned for at least 2 additional months; used to decrease the need for blood transfusions in such patients.1 187 247 288 296 344 348 358 359 400 524 525 527 528 530 534 535 536 537 538 572 583

ESAs not indicated in patients with chemotherapy-induced anemia when the anticipated outcome is cure of the underlying malignancy.1 400 608 ESAs do not improve outcomes of cancer chemotherapy (e.g., in terms of greater tumor shrinkage, delayed tumor progression, increased survival).1 400 589 590 597 599 600 602 603 604 607 608 609 614 Not established that ESAs improve quality of life, fatigue, or patient well-being.1 400 589 590

Not intended for patients who require acute correction of severe anemia; do not use as a substitute for emergency transfusion.1 400

Chronic Anemia Associated with Malignancy

Epoetin alfa and other ESAs not indicated for use in anemic patients with active malignant disease who are not receiving cancer chemotherapy.1 400 597

Has been used for the treatment and prevention of the normocytic, normochromic anemia associated with malignancy;4 10 122 187 247 296 348 349 404 405 411 412 413 461 464 510 518 524 525 529 530 601 however, ESAs have been shown to decrease survival in certain cancer patients who are not receiving chemotherapy or radiation therapy.1 400

Reduction of Allogeneic Blood Transfusions in Anemic Surgical Patients

Treatment of anemic patients (hemoglobin >10 to ≤13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery; used perioperatively to reduce the need for allogeneic blood transfusions.1 161 173 174 187 199 211 239 247 344 377 400 406 419 453 464 510

Indicated for such patients who are at high risk for perioperative blood loss. 1 400

Not intended for patients who require acute correction of severe anemia; do not use as a substitute for emergency transfusion.1 400

Not indicated in patients who are willing to donate autologous blood prior to elective surgery.1 400

Not indicated for reduction of allogeneic RBC transfusions in patients undergoing cardiac or vascular surgery.1 400 597 601 (See Increased Mortality and Cardiovascular and Thromboembolic Events under Cautions.)

Anemia Associated with Rheumatoid Arthritis and Rheumatic Disease

Has been used for treatment of anemia associated with rheumatoid arthritis and/or rheumatic disease.2 4 5 7 10 122 154 174 187 247 336 344 373 420 437 462 464 510

Anemia of Prematurity

May be beneficial in the treatment of anemia of prematurity.2 18 36 37 187 331 336 338 350 453 465 519 562 563 564 Optimal patient selection criteria not established.338 562 563 564

Myelodysplastic Syndrome

Has been used in patients with myelodysplastic syndromes (designated an orphan drug by FDA for this use).460 464 519 531 532 533 Relatively limited response rates reported; effects of the hormone on nonerythroid cell lines and potential risks of leukemic transformation require elucidation.460 464 531 532 533

Misuse and Abuse

Potential exists for abuse of the drug by athletes, especially those participating in high-aerobic demand, endurance-type events.4 21 247 385 386 453 468 469 501 Effects of epoetin alfa would be expected to be similar to those of homologous or autologous RBC cell transfusions (“blood doping”), which have been used by athletes to increase cardiac output, maximal oxygen uptake capacity of blood, and aerobic exercise endurance by increasing arterial blood oxygen content; effects may be particularly evident in individuals with greater initial aerobic fitness.21 340 341 342 343 385 386 501

Abuse by athletes is difficult to detect; no reliable way to distinguish epoetin alfa from the endogenous hormone using readily available drug-screening methods (e.g., immunoradiometric assay).4 385 386

Medical and sports experts, including the US and International Olympic Committees and the National Collegiate Athletic Association, consider the use of epoetin alfa to enhance athletic ergogenic potential inappropriate and unacceptable; use by athletes is contrary to the rules and ethical principles of athletic competition.469 504 508 510 518

Epoetin Alfa Dosage and Administration

General

  • In controlled trials of patients with CKD, ESA therapy targeted to hemoglobin concentrations >11 g/dL did not provide additional benefit beyond that achieved with lower hemoglobin targets and was associated with greater risk of death and serious adverse cardiovascular events; no trial to date has identified a target hemoglobin concentration, ESA dosage, or dosing strategy that does not increase these risks.1 400 624 (See Boxed Warning.) Weigh benefits of epoetin alfa against these risks in patients with CKD.1 400 624 Use lowest dosage necessary to reduce the need for RBC transfusion.1 400 589 590

  • To decrease risks of shortened survival, tumor progression or recurrence in patients with cancer, use lowest dosage sufficient to reduce the need for RBC transfusion and discontinue following completion of a chemotherapy course.1 400

  • Evaluate iron status (i.e., transferrin saturation, serum ferritin) prior to and during therapy.1 400 Administer supplemental iron if serum ferritin <100 mcg/L or transferrin saturation <20%.1 400

  • Exclude or correct other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) prior to initiating therapy.1 400

Restricted Distribution Program in Oncology

  • A required risk management plan (Risk Evaluation and Mitigation Strategy, REMS) has been developed for all ESAs.1 619 (See REMS.)

  • The APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) Oncology program has been created to minimize risk of decreased survival and poor tumor response in cancer patients receiving ESAs.1 619 Clinicians and institutions must enroll in and comply with all requirements of the program (e.g., training module, signed acknowledgment of patient counseling) before they can prescribe and/or dispense ESAs to patients with cancer; participants must re-enroll every 3 years.1 619 For additional information or to enroll in the ESA APPRISE Oncology program, contact 866-284-8089 or visit www.esa-apprise.com.1

Administration

Administer by IV or sub-Q injection.1 IV injection recommended in patients with CKD undergoing hemodialysis.1 400 581 582

Do not dilute or shake prior to use.1 400

Commercially available epoetin alfa injection generally should not be diluted or mixed with other drug solutions except in certain cases of sub-Q administration.1 400 (See Sub-Q Administration under Administration.)

IV Administration

Administer by direct IV injection.1 400

In patients undergoing hemodialysis, injection into the venous return line of the dialysis tubing following dialysis eliminates the need for additional venous access.1 50 51 59 65 66 68 70 112 115 122 138 173 187 233 247 256 306 400

Sub-Q Administration

At the time of administration, preservative-free epoetin alfa (single-use vial) can be admixed in a syringe with bacteriostatic 0.9% sodium chloride injection (preserved with benzyl alcohol) in a 1:1 ratio; presence of benzyl alcohol may ameliorate injection site discomfort.1 400 HID Because of risks of toxicity, do not admix with benzyl alcohol-preserved solutions in neonates, infants, or pregnant or nursing women.1 400

Dosage

Potency of epoetin alfa has been expressed in units of activity per mg of protein268 509 as tested against the WHO Second International Reference Preparation of human urinary erythropoietin.268 355

Pediatric Patients

Anemia of Chronic Kidney Disease
IV or Sub-Q

Children and infants ≥1 month of age on dialysis: Initially, 50 units/kg 3 times weekly; IV administration recommended in patients undergoing hemodialysis.1 400

Initiate therapy when hemoglobin concentration <10 g/dL.1 400 624 Reduce or interrupt therapy if hemoglobin approaches or exceeds 11 g/dL.1 400

Children ≥3 months of age who do not require dialysis: 50–250 units/kg 1–3 times weekly has been used.1 400

Dosage Modifications

Adjust dosage based on hemoglobin concentrations.1 Consider rate of hemoglobin increase or decrease, ESA responsiveness, and hemoglobin variability when determining whether adjustments are needed; a single hemoglobin excursion may not require a dosage change.1 Avoid frequent dosage changes.1

Monitor hemoglobin concentration at least weekly following initiation of therapy and after each dosage adjustment until stable, then at least monthly thereafter.1 400 624

If hemoglobin concentration increases by >1 g/dL in any 2-week period, reduce dosage by 25% or more as necessary to reduce risk of a rapid response.1 400

If hemoglobin has not increased by >1 g/dL after 4 weeks of therapy, increase dosage by 25%.1 400

Do not increase dosage more frequently than once every 4 weeks.1 400 If an adequate response not obtained within 12 weeks, evaluate for other causes of anemia; further dosage increase not likely to improve patient response and may increase risks of therapy.1 400 624 (See Boxed Warning.) Use lowest dosage sufficient to reduce need for RBC transfusions; discontinue drug if responsiveness does not improve.1

Zidovudine-associated Anemia in HIV-infected Patients
IV or Sub-Q

Children 8 months to 17 years of age have received dosages of 50–400 units/kg 2 or 3 times weekly.1 400

Chemotherapy-induced Anemia in Patients with Nonmyeloid Malignancies
IV

Pediatric patients 5–18 years of age: Initially, 600 units/kg once weekly.1 400 583 601

Initiate only if hemoglobin concentration <10 g/dL and at least 2 additional months of chemotherapy is planned.1 400

Discontinue epoetin alfa therapy following completion of a course of chemotherapy.1 400 589 590 (See Boxed Warning.)

Dosage Modifications

Monitor hemoglobin concentrations at least weekly following initiation of therapy and after each dosage adjustment until stable and sufficient to minimize need for RBC transfusions.1 400

If the hemoglobin has not increased by ≥1 g/dL within 4 weeks and remains <10 g/dL, increase weekly dosage to 900 units/kg (maximum 60,000 units weekly).1 400

If hemoglobin increases by >1 g/dL in any 2-week period or reaches a concentration sufficient to avoid RBC transfusion, reduce dosage by 25%.1 400 If hemoglobin exceeds a level needed to avoid RBC transfusion, withhold therapy until the hemoglobin falls to a level where RBC transfusion may be required, then resume at a dosage 25% less than the previous dosage.1 400 601

Discontinue epoetin alfa therapy after 8 weeks if no response based on hemoglobin concentrations or if RBC transfusions are still required.1 400

Adults

Anemia of Chronic Kidney Disease
IV or Sub-Q

Patients on dialysis: Initially, 50–100 units/kg 3 times weekly; IV administration recommended in patients undergoing hemodialysis.1 400 Initiate therapy when hemoglobin concentration <10 g/dL.1 400 624 Reduce or interrupt therapy if hemoglobin approaches or exceeds 11 g/dL.1 400 (See Boxed Warning.)

Patients not on dialysis: Initially, 50–100 units/kg 3 times weekly.1 400 Consider initiating therapy when hemoglobin <10 g/dL and the following 2 conditions apply: rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion and a goal of therapy is to reduce risk of alloimmunization and/or other risks associated with RBC transfusions.1 400 Reduce or interrupt therapy if hemoglobin >10 g/dL.1 400 (See Boxed Warning.)

Dosage Modifications

Adjust dosage based on hemoglobin concentrations.1 400 Consider rate of hemoglobin increase or decrease, ESA responsiveness, and hemoglobin variability when determining whether adjustments are needed; a single hemoglobin excursion may not require a dosage change.1 400 Avoid frequent dosage changes.1 400

Monitor hemoglobin concentration at least weekly following initiation of therapy and after each dosage adjustment until stable, then at least monthly thereafter.1 400

If hemoglobin increases by >1 g/dL in any 2-week period, reduce dosage by 25% or more as necessary to reduce risk of a rapid response.1 400

If hemoglobin has not increased by >1 g/dL after 4 weeks of therapy, increase dosage by 25%.1 400

Do not increase more frequently than once every 4 weeks.1 400 If an adequate response not obtained within 12 weeks, evaluate for other causes of anemia.1 400 (See Lack or Loss of Response to Therapy under Cautions.) Further dosage increases are not likely to improve patient response and may increase risks of therapy; use lowest dosage sufficient to reduce need for RBC transfusions and discontinue drug if responsiveness does not improve.1 400 (See Boxed Warning.)

Zidovudine-associated Anemia in HIV-infected Patients
IV or Sub-Q

Initially, 100 units/kg 3 times weekly in patients with endogenous serum erythropoietin concentrations ≤500 milliunits/mL receiving ≤4.2 g/week of zidovudine.1 400 601

Dosage Modifications

Monitor hemoglobin concentration at least weekly following initiation of therapy and after each dosage adjustment until stable and sufficient to minimize need for RBC transfusions.1 400

If hemoglobin does not increase after 8 weeks, increase the 3-times-weekly dose by 50–100 units/kg at 4- to 8-week intervals until an adequate hemoglobin concentration or a dosage of 300 units/kg 3 times weekly is reached.1 400 Discontinue therapy if hemoglobin does not increase after 8 weeks of treatment with 300 units/kg 3 times weekly.1 400

If hemoglobin >12 g/dL, withhold therapy until hemoglobin decreases to <11 g/dL.1 400 Reduce dosage by 25% upon reinitiation.1 400

Chemotherapy-induced Anemia in Patients with Nonmyeloid Malignancies
Sub-Q

Initiate only if hemoglobin concentration <10 g/dL and at least 2 additional months of chemotherapy is planned.1 400 Discontinue following completion of a chemotherapy course.1 400

3-times-weekly regimen: Initially, 150 units/kg 3 times weekly.1 400

Once-weekly regimen: Initially, 40,000 units weekly.1 400

Dosage Modifications

3-times-weekly regimen: If hemoglobin concentration has not increased by ≥1 g/dL within 4 weeks and remains <10 g/dL, increase dosage to 300 units/kg 3 times weekly.1 400

Once-weekly regimen: If hemoglobin has not increased by ≥1 g/dL within 4 weeks and remains <10 g/dL, increase dosage to 60,000 units weekly.1 400

If hemoglobin reaches a concentration sufficient to avoid the need for RBC transfusion or increases by >1 g/dL in any 2-week period, reduce dosage by 25%.1 400 If the hemoglobin exceeds a concentration needed to avoid RBC transfusion, temporarily withhold therapy until the hemoglobin falls to a concentration where RBC transfusion may be required, then resume at a dosage 25% less than the previous dosage.1 400 601

Discontinue therapy after 8 weeks if no response based on hemoglobin concentrations or if RBC transfusions are still required.1 400

Reduction of Allogeneic RBC Transfusions in Anemic Surgical Patients
Sub-Q

Prior to therapy, obtain hemoglobin to ensure concentration >10 but ≤13 g/dL.1 400

300 units/kg once daily for 10 days prior to surgery, on the day of surgery, and for 4 days after surgery.1 400

Alternatively, 600 units/kg once weekly for 3 weeks prior to surgery (i.e., days 21, 14, and 7 before surgery), with an additional dose given on the day of surgery.1 400

Prescribing Limits

Pediatric Patients

Chemotherapy-induced Anemia in Patients with Nonmyeloid Malignancies
IV

Maximum 60,000 units once weekly.1 400

Adults

Zidovudine-associated Anemia in HIV-infected Patients
IV or Sub-Q

Patients not responding to 300 units/kg 3 times weekly are unlikely to respond to higher dosages.1 400

Special Populations

Geriatric Patients

Patients with CKD: Individualize dosing.1 400

Cancer patients receiving concomitant chemotherapy: Dosage requirements similar to those in younger adults.1 400

Surgical patients: Dosage requirements similar to those in younger adults.1 400

Cautions for Epoetin Alfa

Contraindications

  • Uncontrolled hypertension.1 400

  • Pure red cell aplasia (PRCA) following treatment with epoetin alfa or other erythropoietin proteins.1 400

  • Serious allergic reactions to epoetin alfa.1 400

Warnings/Precautions

Warnings

Increased Mortality and Cardiovascular and Thromboembolic Events

Increased risk of death and serious cardiovascular events reported in patients with CKD receiving therapy with epoetin alfa and other ESAs targeted to hemoglobin concentrations >11 g/dL.1 400 585 586 587 594 595 610 615 620 622 624 (See Boxed Warning.) In controlled clinical studies comparing higher (13–14 g/dL) to lower (9–11.3 g/dL) hemoglobin targets, an increased risk of death, MI, stroke, CHF, hemodialysis vascular access thrombosis, and other thromboembolic events was observed in the higher target groups.1 60 400 585 586 590 610 620 622 624 625 Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at greater risk.1 400 597 Increases in hemoglobin >1 g/dL during any 2-week period also may contribute to these risks.1 400

Increased mortality reported in patients (without CKD) undergoing coronary artery bypass and receiving perioperative epoetin alfa; death associated with thrombotic events reported during drug administration.1 400 612 ESAs are not indicated for reduction of allogeneic RBC transfusions in patients undergoing cardiac surgery.1 400

Increased mortality and incidence of fatal thrombotic vascular events reported in women with metastatic breast cancer receiving cancer chemotherapy and ESAs targeted to hemoglobin concentrations of 12–14 g/dL.1 400 (See REMS and see also Boxed Warning.)

Increased incidence of thromboembolic events also observed in patients undergoing orthopedic surgical procedures without prophylactic anticoagulation and receiving epoetin alfa to reduce allogeneic RBC transfusion requirements.1 400 589 590 Antithrombotic prophylaxis strongly recommended when ESAs are used in such patients.1 400

Correction of hemoglobin to concentrations >11 g/dL may increase risk of serious and life-threatening cardiovascular events in patients with CKD.1 400 584 585 586 587 588 589 590 624 The manufacturer and FDA recommend that treatment be initiated in patients with CKD only when hemoglobin concentration <10 g/dL.1 400 595 624 Use lowest dosage sufficient to reduce the need for transfusions.1 400 624

Increased anticoagulation with heparin may be needed during dialysis to prevent clotting of the extracorporeal circuit.1 400

Increased Mortality and/or Tumor Progression

Risk of increased mortality and tumor progression or recurrence in patients with cancer.1 400 (See Boxed Warning.)

Decreased overall survival observed in patients with non-small-cell lung cancer receiving only palliative radiotherapy or no active therapy and epoetin alfa targeted to a hemoglobin concentration of 12–14 g/dL.1 400 590 597

Shortened time to tumor progression observed in patients with advanced head and neck cancer receiving only radiation therapy and an ESA.1 400 600

An increased risk of death and no reduction in transfusion requirements observed in patients with cancer-related anemia who were not receiving cancer chemotherapy or radiation therapy while receiving another ESA, darbepoetin alfa.1 400 589 590

ESAs, including epoetin alfa, can only be prescribed and dispensed to cancer patients by authorized clinicians and institutions enrolled in the ESA APPRISE Oncology program.1 619 (See Restricted Distribution Program in Oncology under Dosage and Administration and also see REMS.)

Hypertension and Seizures

Risk of new or worsening hypertension in patients with CKD, particularly during early phase of therapy.1 3 6 10 11 21 23 27 29 38 48 49 54 57 59 65 100 115 119 122 135 227 283 324 366 395 400 488 May require initiation of or increases in antihypertensive therapy.1 400 (See Advice to Patients.)

Monitor and appropriately control BP prior to and during therapy; reduce or withhold epoetin alfa if BP becomes difficult to control.1 400 Contraindicated in patients with uncontrolled hypertension.1 400

Seizures and hypertensive encephalopathy reported; risk appears greater in patients with CKD.1 400 Monitor closely for premonitory neurologic symptoms during first several months of therapy.1 400 (See Advice to Patients.)

Potential for Transmission of Viral Diseases

Contains albumin, a derivative of human blood; risk of transmitting viral diseases and/or Creutzfeldt-Jakob Disease (CJD) appears to be extremely remote.1 400 No cases of transmission of viral diseases or CJD ever identified for albumin.1 400

Pure Red Cell Aplasia

PRCA and severe anemia with or without other cytopenias reported in association with neutralizing antibodies to endogenous erythropoietin.1 400 581 582

PRCA occurred predominantly in patients with CKD receiving ESAs by sub-Q administration.1 400 581 582 PRCA also reported in patients with hepatitis C virus (HCV) infection receiving ESAs for anemia related to hepatitis treatment (non-FDA-labeled indication).1 616 617

Withhold therapy in any patient who develops severe anemia and low reticulocyte counts; evaluate for presence of neutralizing antibodies to erythropoietin.1 400 581 582 Contact the manufacturer (Janssen Biotech [formerly Centocor Ortho Biotech] at 800-457-6399, Amgen at 800-772-6436) to perform assays for binding and neutralizing antibodies.1 400 581 582

Discontinue permanently in any patient with PRCA.1 400 (See Contraindications.) Do not switch to another ESA.1 400

Sensitivity Reactions

Risk of severe allergic reactions, including anaphylactic reactions, angioedema, respiratory symptoms, skin rash, and urticaria.1 400 Discontinue immediately and initiate appropriate therapy if a serious allergic or anaphylactic reaction occurs; do not reinitiate.1 400

General Precautions

Patient Monitoring

Monitor hemoglobin concentrations weekly following initiation of therapy and after each dosage change until stable and sufficient to minimize RBC transfusions.1 400

Regularly monitor CBC, including reticulocyte count, blood cell differential, platelet count, and determination of erythrocyte indices (Wintrobe indices).1 70 114 245 400 510

Evaluate iron stores (i.e., transferrin saturation, serum ferritin) prior to and during therapy.1 400 583 Administer supplemental iron if transferrin saturation <20% or serum ferritin concentration <100 mcg/L.1 400 Virtually all patients with CKD will require supplemental iron.1 400 3 5 25 32 50 53 54 70 81 101 119 122 135 173 187 228 229 247 298 313 324 336 400 422

Lack or Loss of Response to Therapy

Evaluate patients who fail to respond or experience a loss of hemoglobin response for potential causative factors (e.g., iron deficiency, infection, inflammation, bleeding).1 400

In the absence of another etiology, evaluate for PRCA and test for presence of antibodies to erythropoietins.1 400 581 582 (See Pure Red Cell Aplasia under Cautions.)

Specific Populations

Pregnancy

Category C.1 400 Use during pregnancy only when potential benefits justify risks to the fetus; if used, use only single-dose formulation without benzyl alcohol.1 112 122 187 400 Women who become pregnant during epoetin alfa therapy are encouraged to enroll in the manufacturer’s Pregnancy Surveillance Program by calling 800-772-6436.1

Lactation

Not known whether epoetin alfa is distributed into human milk; use with caution in nursing women.1 122 187 400

When epoetin alfa therapy is needed during nursing, use a benzyl alcohol-free formulation.1

Pediatric Use

Safety and efficacy for treatment of anemia of CKD established in children and infants ≥1 month of age undergoing dialysis.1 400 Pattern of adverse effects similar to that reported in adults.1 400 Safety and efficacy not established in pediatric patients with CKD not on dialysis.1 400

Safety and efficacy established for the treatment of chemotherapy-induced anemia in pediatric patients ≥5 years of age.1 400 Adverse effects similar to those experienced in adults.1 400

Has been used for treatment of zidovudine-associated anemia in pediatric patients 8 months to 17 years of age.1 400

Has been used in pediatric patients for the treatment of anemia of prematurity.331 338 465 518 547 550

Commercially available multidose vials of epoetin alfa contain benzyl alcohol as a preservative,1 400 which has been associated with neurologic and other toxicity in neonates.1 400 556 557 558 559 560 561 Do not use epoetin alfa from multidose vials or from single-dose vials that have been admixed with bacteriostatic saline preserved with benzyl alcohol in neonates or infants.1 400

Geriatric Use

Patients with anemia associated with CKD or cancer chemotherapy: No overall differences in safety and efficacy relative to younger adults.1 400

Zidovudine-treated HIV-infected patients: Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1 400

Surgical patients: No overall differences in safety and efficacy relative to younger adults.1 400

Although special precautions usually not necessary,510 518 careful monitoring of blood chemistry and BP may be necessary because of a general increased risk of renal and/or cardiovascular complications in geriatric patients.510 518

Common Adverse Effects

Patients with CKD: Hypertension, 1 3 4 5 6 10 11 16 21 23 25 27 29 38 46 47 48 49 50 52 53 54 56 57 59 61 65 74 84 86 90 100 104 105 106 112 114 115 119 122 135 166 187 189 214 227 233 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 261 276 298 299 300 312 315 323 324 336 366 394 395 400 401 414 426 400 arthralgias1 400 , muscle spasm,1 400 pyrexia,1 400 dizziness,1 400 medical device malfunction,1 400 vascular occlusion,1 400 upper respiratory tract infection.1 400

HIV-infected patients: Pyrexia, cough, rash, injection-site irritation.1 400

Cancer patients: Nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, insomnia, headache, depression, dysphagia, hypokalemia, thrombosis.1 400

Patients undergoing surgery: Nausea, vomiting, pruritus, injection-site pain, chills, deep-vein thrombosis, cough, hypertension, headache.1 400

Interactions for Epoetin Alfa

Specific Drugs

Drug

Interaction

Comments

Androgens

Possible increase in the sensitivity of erythroid progenitors425

Has been used for therapeutic effect 425

Desmopressin

Potential decrease in bleeding time39

Probenecid

Possible pharmacokinetic interaction187

Epoetin Alfa Pharmacokinetics

Absorption

Bioavailability

Following sub-Q administration, peak plasma concentrations achieved within 5–24 hours.1 400

Serum concentrations peak sooner and are substantially higher with IV compared with sub-Q injection, concentrations are less sustained; IV route of administration generally offers no clinical advantage.445 453 466 510

Sub-Q injection 3 times weekly can produce a hemoglobin response similar to that following IV injection but at lower dosages;41 466 518 dosages required for maintenance therapy generally are lower with sub-Q than IV injection.466 505

Onset

Increase in hemoglobin concentrations: 2–6 weeks.1 400

Distribution

Extent

Not fully elucidated.1 400

Not known whether epoetin alfa crosses the placenta or is distributed into milk.1 150 353 375 376 400 464

Special Populations

In preterm neonates, distribution volume approximately 1.5–2 times larger than in healthy adults.400

Elimination

Metabolism

Metabolic fate of endogenous erythropoietin and the recombinant hormone (i.e., epoetin alfa) poorly understood.21 174 187 304 308 381 466 Hepatic metabolism contributes only minimally to elimination of the intact hormone.187 308 466

Elimination Route

Approximately ≤10% is excreted unchanged in urine.6 53 187 188 200 249 344

Half-life

IV administration in healthy individuals and in patients with CKD: 4–16 hours.1 2 6 12 19 21 44 51 103 122 147 166 174 200 222 247 291 304 309 337 344 345 366 400 431 445 450 453

Special Populations

Elimination half-life does not appear to be affected by hemodialysis.1 187 400 518 The elimination characteristics of epoetin alfa appear to be similar in patients undergoing hemodialysis or peritoneal dialysis.466

Half-life similar in adults >65 or <65 years of age.400

In preterm neonates, clearance approximately 3 times higher than in healthy adults.400

Stability

Storage

Parenteral

Injection

Refrigerate at 2–8°C; do not freeze or shake.1 187 251 304 306 366 400 467 Protect from light.1 400

Store unused portions of multidose vial at 2–8°C and discard 21 days after initial entry into vial.1 400

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution CompatibilityHID

Compatible

Dextrose 10% in water with albumin human 0.05 or 0.1%

Incompatible

Dextrose 10% in water

Dextrose 10% in water with albumin human 0.01%

Sodium chloride 0.9%

Actions

Advice to Patients

  • Importance of informing patients about the increased risks of death, serious cardiovascular effects, thromboembolic events, and tumor progression in certain patient populations.1 400 (See Increased Mortality and Cardiovascular and Thromboembolic Events under Cautions and also see Boxed Warning.)

  • Patient instructions for use and medication guide must be provided prior to initiating therapy and each time drug is dispensed.1 400 598 615 619

  • If the patient or caregiver is to administer epoetin alfa, provide careful instructions regarding proper, safe use of the drug in this setting, including information on aseptic techniques and on storage and disposal of the drug and administration equipment.1 400 598 615 Advise such patients to follow the manufacturer’s “Patient Instructions for Use”.1

  • Importance of informing clinicians of heart disease, high BP, history of seizures or strokes, and blood disorders (e.g., sickle cell anemia, clotting disorders) prior to treatment initiation.598 615

  • Importance of informing patients of the risks associated with benzyl alcohol (preservative in some epoetin alfa formulations) in neonates, infants, pregnant and nursing women.1 400

  • Importance of informing patients of possible adverse effects, including signs and symptoms of allergic drug reactions.1 598 615 Importance of informing clinicians immediately if serious allergic reaction occurs (e.g., whole body rash, shortness of breath, wheezing, decreases in BP, swelling around mouth or eyes, fast pulse, sweating).598 615 Importance of advising patients of appropriate actions to take if adverse effects occur.1 584 598 615

  • Importance of reporting signs or symptoms of chest pain, pain in the legs with or without swelling, stroke, irregular heartbeats, seizures, confusion, dizziness or loss of consciousness, extreme tiredness, blood clots in hemodialysis vascular access ports, or increases in BP.598 615

  • Risk of seizures; importance of patients contacting a clinician if any new-onset seizures, premonitory symptoms, or change in seizure frequency occurs.1 400

  • Importance of informing clinician of redness, swelling, or itching at the injection site.598 615

  • Importance of adherence to antihypertensive treatment and dietary restrictions.1 400

  • Importance of regular monitoring of BP and hemoglobin concentration and of keeping appointments for determination of hemoglobin concentrations.1 400 584 588 590 598 615

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.1 400

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 400 598 615

  • Importance of informing patients of other important precautionary information.1 400 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Because of risks associated with use of erythropoiesis-stimulating agents (ESAs) in cancer patients, the APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) Oncology program has been developed.1 619 For additional information, see Restricted Distribution Program in Oncology under Dosage and Administration: Administration.

Epoetin Alfa (Recombinant DNA Origin)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Injection, for IV or subcutaneous use

2000 units/mL

Epogen

Amgen

Procrit

Janssen Biotech, (formerly Centocor Ortho Biotech)

3000 units/mL

Epogen

Amgen

Procrit

Janssen Biotech, (formerly Centocor Ortho Biotech)

4000 units/mL

Epogen

Amgen

Procrit

Janssen Biotech, (formerly Centocor Ortho Biotech)

10,000 units/mL

Epogen

Amgen

Procrit

Janssen Biotech, (formerly Centocor Ortho Biotech)

20,000 units/mL

Epogen

Amgen

Procrit

Janssen Biotech, (formerly Centocor Ortho Biotech)

40,000 units/mL

Epogen

Amgen

Procrit

Janssen Biotech, (formerly Centocor Ortho Biotech)

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Epogen 10000UNIT/ML Solution (AMGEN): 2/$292.51 or 6/$854.19

Epogen 10000UNIT/ML Solution (AMGEN): 10/$1,356.86 or 30/$3,989.79

Epogen 2000UNIT/ML Solution (AMGEN): 1/$40.28 or 3/$112.79

Epogen 20000UNIT/ML Solution (AMGEN): 10/$2,731.05 or 30/$7,970.13

Epogen 3000UNIT/ML Solution (AMGEN): 1/$51.36 or 3/$137.97

Epogen 4000UNIT/ML Solution (AMGEN): 1/$63.45 or 10/$568.07

Procrit 10000UNIT/ML Solution (JANSSEN PRODUCTS): 6/$1,086.03 or 18/$3,234.96

Procrit 2000UNIT/ML Solution (JANSSEN PRODUCTS): 6/$243.31 or 18/$697.43

Procrit 20000UNIT/ML Solution (JANSSEN PRODUCTS): 1/$383.99 or 3/$1,144.99

Procrit 3000UNIT/ML Solution (JANSSEN PRODUCTS): 6/$322.98 or 18/$942.96

Procrit 4000UNIT/ML Solution (JANSSEN PRODUCTS): 6/$476.15 or 18/$1,401.14

Procrit 40000UNIT/ML Solution (JANSSEN PRODUCTS): 4/$3,002.09 or 8/$5,899.15

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions January 30, 2012. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Amgen, Inc. Epogen (epoetin alfa) prescribing information. Thousand Oaks, CA; 2011 Jun.

2. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anæmia and the stimulation of erythropoiesis. Drugs. 1989; 38:863-99. [PubMed 2693045]

3. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316:73-78. [IDIS 224456] [PubMed 3537801]

4. Winearls C. Erythropoietin—advent of a new treatment. Practitioner 1987; 231:1269-73. [PubMed 3333088]

5. Schwenk MH, Halstenson CE. Recombinant human erythropoietin. DICP. 1989; 23:528-36. [IDIS 256984] [PubMed 2669369]

6. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Ann Intern Med. 1989; 110:108-14. [IDIS 250512] [PubMed 2909202]

7. Means RT, Olsen NJ, Krantz SB et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arth Rheum. 1989; 32:638-42.

8. Rodgers GP, Lessin LS. Recombinant erythropoietin improves the anemia associated with Gaucher’s disease. Blood. 1989; 73:2228-9. [IDIS 255961] [PubMed 2730957]

9. Geissler K, Stockenhuber F, Kabrna E et al. Recombinant human erythropoietin and hematopoietic progenitor cells in vivo. Blood. 1989; 73:2229. [IDIS 255962] [PubMed 2730958]

10. Klingemann HG. Clinical applications of recombinant human colony-stimulating factors. CMAJ. 1989; 140:137-42. [IDIS 251163] [PubMed 2642725]

11. Sinai-Trieman L, Salusky IB, Fine RN. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr. 1989; 114:550-4. [IDIS 253795] [PubMed 2926567]

12. Macdougall IC, Roberts DE, Neubert P et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet. 1989; 1:425-7. [IDIS 251879] [PubMed 2563798]

13. Metcalf D. Hæmopoietic growth factors 1. Lancet. 1989; 1:825-7. [IDIS 253599] [PubMed 2564910]

14. Metcalf D. Hæmopoietic growth factors 2: clinical applications. Lancet. 1989; 1:885-7. [IDIS 253662] [PubMed 2564958]

15. Zachee P, Staal GE, Rijksen G et al. Pyruvate kinase deficiency and delayed clinical response to recombinant human erythropoietin treatment. Lancet. 1989; 1:1327-8. [IDIS 256015] [PubMed 2566852]

16. Stevens JM, Strong CA, Oliver DO et al. Subcutaneous erythropoietin and peritoneal dialysis. Lancet. 1989; 1:1388-9. [IDIS 256687] [PubMed 2567400]

17. Macdougall IC, Roberts DE, Coles GA et al. Intraperitoneal erythropoietin. Lancet. 1989; 1:1389. [IDIS 256688] [PubMed 2567401]

18. Christensen RD. Recombinant erythropoietic growth factors as an alternative to erythrocyte transfusion for patients with “anemia of prematurity.” Pediatrics. 1989; 83:793-6. (IDIS 254335)

19. Cotes PM, Pippard MJ, Reid CD et al. Characterization of anemia of chronic renal failure & mode of its correction by a preparation of human erythropoietin (r-huepo): an investigation of the pharmacokinetics of IV erythropoietin and its effects on erythrokinetics. Q J Med. 1989; 70:113-37. [IDIS 255616] [PubMed 2594953]

20. Van Wyck DB, Stivelman JC, Ruiz J et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int. 1989; 35:712-6. [IDIS 256549] [PubMed 2709674]

21. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35:134-48. [IDIS 256550] [PubMed 2651751]

22. Paganini EP. Recombinant human erythropoietin therapy: introduction. Semin Nephrol. 1989; 9:1-2.

23. Paganini EP. Overview of anemia associated with chronic renal disease: primary and secondary mechanisms. Semin Nephrol. 1989; 9:3-8. [IDIS 256552] [PubMed 2648518]

24. Korbet SM. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease. Semin Nephrol. 1989; 9:9-15. [IDIS 256553] [PubMed 2648520]

25. Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol. 1989; 9:16-21. [IDIS 256554] [PubMed 2648516]

26. Lundin AP. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol. 1989; 9:22-9. [IDIS 256555] [PubMed 2648517]

27. Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol. 1989; 9:30-4. [IDIS 256556] [PubMed 2648519]

28. Zehnder C. Erythropoietin treatment: influence of hæmoglobin concentration on dialyser creatinine clearance in hæmodialysed patients. Nephron. 1989; 51:424-5. [IDIS 256558] [PubMed 2918959]

29. Wine.dtd CG. Treatment of anæmia in hæmodialysis patients with recombinant erythropoietin. Nephron. 1989; 51:26-8. (IDIS 256560)

30. Verbeelen D, Bossuyt A, Smitz J et al. Hemodynamics of patients with renal failure treated with recombinant human erythropoietin. Clin Nephrol. 1989; 31:6-11. [IDIS 256561] [PubMed 2914412]

31. Schaefer RM, Kokot F, Wernze H et al. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin. Clin Nephrol. 1989; 31:105.

32. Stone WJ, Graber SE, Krantz SB et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci. 1988; 171-9. (IDIS 246785)

33. Cotes PM. Erythropoietin: the developing story. BMJ. 1988; 296:805-6. [IDIS 256570] [PubMed 3130919]

34. Johnson CA, Chester MI. Pathophysiology and treatment of the anemia of renal failure. Clin Pharm. 1988; 7:117- 22. [IDIS 238155] [PubMed 3280218]

35. Watson AJ, Spivak JL. Recombinant human erythropoietin therapy in end stage renal failure. J Clin Pharmacol. 1988; 28:1086-8. [IDIS 251301] [PubMed 3072351]

36. Rhondeau SM, Christensen RD, Ross MP et al. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the “anemia of prematurity.” J Pediatr. 1988; 112:935-40. (IDIS 245713)

37. Stockman JA. Erythropoietin: off again, on again. J Pediatr. 1988; 112:906-8. [IDIS 256569] [PubMed 3373395]

38. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet. 1988; 1:97-100. [IDIS 237859] [PubMed 2891990]

39. Jacquot C, Masselot JP, Berthelot JM et al. Addition of desmopressin to recombinant human erythropoietin in treatment of hæmostatic defect of uraemia. Lancet. 1988; 1:420. [IDIS 238681] [PubMed 2893223]

40. Vallance P, Benjamin N, Collier J. Erythropoietin, hæmoglobin, and hypertensive crises. Lancet. 1988; 1:1107. [IDIS 241441] [PubMed 2896933]

41. Bommer J, Ritz E, Weinreich T et al. Subcutaneous erythropoietin. Lancet. 1988; 2:406. [IDIS 245119] [PubMed 2899821]

42. Zaoui P, Bayle F, Maurizi J et al. Early thrombosis in kidney grafted into patient treated with erythropoietin. Lancet. 1988; 2:1495.

43. Nienhuis AW. Hematopoietic growth factors: biologic complexity and clinical promise. N Engl J Med. 1988; 318:916-8. [IDIS 240414] [PubMed 3281008]

44. Boelaert JR, Schurgers ML, Matthys EG et al. Pharmacokinetics of rHuEPO in CAPD patients: comparison of the IV, SC, and IP routes. Pharm Weekbl. 1988; 10:291.

45. Schaefer RM, Kokot F, Kröner B et al. Normalization of elevated prolactin levels in hemodialysis patients on erythropoietin. Nephron. 1988; 50:400-1. [IDIS 250752] [PubMed 3237289]

46. Zehnder C, Glück Z, Descoeudres C et al. Human recombinant erythropoietin in anaemic patients on maintenance hæmodialysis: secondary effects of the increase of hæmoglobin. Nephrol Dial Transplant. 1988; 3:657-60. [IDIS 256559] [PubMed 3146724]

47. Beer J. Treatment of anaemia in chronic renal failure. Nurs Times. 1988; 84:55-7. [IDIS 256563] [PubMed 3211795]

48. Mayer G, Thum J, Cada EM et al. Working capacity is increased following recombinant human erythropoietin. Kidney Int. 1988; 34:525-8. [IDIS 256564] [PubMed 3199672]

49. Akizawa T, Koshikawa S, Takaku F et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure: a multi-institutional study in Japan. Int J Artif Organs. (IDIS 256565)

50. Schaefer PM, Kuerner B, Zech M et al. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int J Artif Organs. 1988; 11:249-54. [IDIS 256566] [PubMed 3410565]

51. Urabe A, Takaku F, Mizoguchi H et al. Effect of recombinant human erythropoietin on the anemia of chronic renal failure. Int J Cell Cloning. 1988; 6:179-91. [IDIS 256567] [PubMed 3397592]

52. Schwartz AB, Prior J, Terzian L et al. Erythropoietin for the anemia of chronic renal failure. Am Fam Physician. 1988; 37:211-5. [IDIS 256568] [PubMed 3289343]

53. Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis. 1988; 11:203-9. [IDIS 256572] [PubMed 3278599]

54. Casati S, Passerini P, Campise MR et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. BMJ. 1987; 295:1017-20. [IDIS 235359] [PubMed 3120854]

55. Glassock RJ. Nephrology. JAMA. 1987; 258:2256- 8.

56. Jacquot C, Ferragu-Haguet M, Lefebvre A et al. Recombinant erythropoietin and blood pressure. Lancet. 1987; 2:1083. [IDIS 235716] [PubMed 2889986]

57. Moia M, Mannucci PM, Vizzotto L et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet. 1987; 2:1227-9. [IDIS 236018] [PubMed 2890852]

58. Anon. Erythropoietin. Lancet. 1987; 1:781-2. [PubMed 2882187]

59. Bommer J, Müller-Bühl E, Ritz E et al. Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet. 1987; 1:392. [IDIS 256575] [PubMed 2880204]

60. Erslev A. Erythropoietin coming of age. N Engl J Med. 1987; 316:101-3. [IDIS 224457] [PubMed 3785351]

61. Ahmad R, Hand M. Recombinant erythropoietin for the anemia of chronic renal failure. N Engl J Med. 1987; 317:169. [IDIS 232625] [PubMed 3600706]

62. Walczyk MH, Golper TA. Correction of the anemia of end- stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987; 317:249. [IDIS 256576] [PubMed 3600716]

63. Freedman BI, Barbour GL. Correction of the anemia of end- stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987; 317:249-50. [IDIS 256576] [PubMed 3600716]

64. Eschbach JW, Adamson JW. Correction of the anemia of end- stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987; 317:250-1.

65. Bommer J, Alexiou C, Müller-Bühl U et al. Recombinant human erythropoietin therapy in haemodialysis patients—dose determination and clinical experience. Nephrol Dial Transplant. 1987; 2:238-42. [IDIS 256571] [PubMed 3118264]

66. Wine.dtd CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986; 2:1175-8. (IDIS 256574)

67. Nathan DG. Regulation of erythropoiesis. N Engl J Med. 1977; 296:685-7. [IDIS 70097] [PubMed 840258]

68. Zins B, Drüeke T, Zingraff J et al. Erythropoietin treatment in anaemic patients on haemodialysis. Lancet. 1986; 2:1329. [IDIS 223562] [PubMed 2878188]

69. Frenken LAM, Coppens PJW, Tiggeler RGWL et al. Intraperitoneal erythropoietin. Lancet. 1988; 2:1495.

70. Anon. Recombinant human erythropoietin product approved for use in chronic renal failure. Clin Pharm. 1989; 8:531.

71. Black WJ. Drug products of recombinant DNA technology. Am J Hosp Pharm. 1989; 46:1834-44. [PubMed 2679063]

72. Jacobs K, Shoemaker C, Rudersdorf R et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985; 313:806-10. [PubMed 3838366]

73. Brown CD, Friedman EA. Stable renal function and benign course in azotemic diabetics treated with erythropoietin (EPO) for one year. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:2. Abstract.

74. Buckner FS, Eschbach JW, Haley NR et al. Correction of the anemia in hemodialysis (HD) patients (pts) with recombinant human erythropoietin (rHuEPO): hemodynamic changes and risks for hypertension. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:2. Abstract.

75. Eschbach JW, Kelly MR, Haley NR et al. Correction of anemia in progressive renal failure with recombinant human erythropoietin (rHuEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:3. Abstract.

76. Haley NR, Matsumoto AM, Eschbach JW et al. Low testosterone (T) levels increase in male hemodialysis patients (HDP) treated with recombinant human erythropoietin (rHuEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11- 14, 1988. Thorofare, NJ: Special Projects Network; 1988:3. Abstract.

77. Hampl H, Riedel E, Wendel G et al. Osmotic fragility of red blood cells (RBC) in hemodialysis (HD) patients with erythropoietin (rHuEPO) therapy. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:4. Abstract.

78. Canadian Erythropoietin Study Group. Description and performance characteristics of a kidney disease specific questionnaire (KDQ) in a clinical trial of recombinant human erythropoietin (EPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:4. Abstract.

79. Opsahl JA, Halstenson CE, Rachael KM et al. Recombinant human erythropoietin (EPO) in chronic renal failure (CRF): no adverse effect on renal hemodynamics or progression of disease. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11- 14, 1988. Thorofare, NJ: Special Projects Network; 1988:5. Abstract.

80. Hori K, Kumagai H, Onoyama K et al. Effects of erythropoietin on anemia and hemodynamics in chronic renal failures without dialysis treatment. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:5. Abstract.

81. Kleinman KS, Schweitzer SU, Perdue ST et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effects on renal function: a double blind placebo controlled trial. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:6. Abstract.

82. Abraham PA, Opsahl JA, McLain LA et al. Determinants of blood pressure (BP) during chronic erythropoietin (EPO) therapy (Rx) in hemodialysis (HD) patients. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:6. Abstract.

83. Acchiardo S, Moore L, Miles D et al. Does erythropoietin (EPO) treatment change hemodialysis (HD) requirements? Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:7. Abstract.

84. Akiba T, Kurihara S, Katoh H et al. Hemodynamic changes of hemodialyzed patients by erythropoietin (EPO) treatment. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11- 14, 1988. Thorofare, NJ: Special Projects Network; 1988:7. Abstract.

85. Berkley V, Fouad F, Currie P et al. Serial echocardiographic evaluation of chronic hemodialysis (CHD) pts during long-term correction of anemia with recombinant human erythropoietin (rHuEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:8. Abstract.

86. Collins A, Keshaviah P, Berkseth R et al. Impact of erythropoietin (EPO) therapy (Rx) on rapid high efficiency hemodialysis (RHED). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:8. Abstract.

87. Dosquet P, Haddoum F, Sporer P et al. In vitro multilineage increase of bone marrow haemotopoietic progenitors from haemodialysed patients treated with recombinant human erythropoietin (rHuEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:9. Abstract.

88. Düreke T, Zins B, Moynot A et al. Kinetics of erythropoiesis in hemodialysis patients (HD pts) on recombinant erythropoietin (rHuEPO) treatment. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:9. Abstract.

89. Evans RW, Rader B, Egrie J et al. Correction of anemia with recombinant human erythropoietin (rHuEPO) enhances the quality of life of hemodialysis (HD) patients (pts). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:10. Abstract.

90. Gibilaro SD, Delano BG, Quinn R et al. Improved quality of life while receiving recombinant erythropoietin (rHuEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11- 14, 1988. Thorofare, NJ: Special Projects Network; 1988:10. Abstract.

91. Iseki K, Hori K, Onoyama K et al. Comparison of hemodynamic effects of blood transfusion and erythropoietin in chronic hemodialysis patients. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:11. Abstract.

92. Kurihara S, Akiba T, Kawabe M et al. Change of hematopoietic response to recombinant erythropoietin (rHuEPO) in hemodialyzed patients. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:11. Abstract.

93. Lazarus JM, Hakim RM, Newell J. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis. 1990; 16:101-8. [PubMed 2382644]

94. Laver MC, MacCarthy EP, Clyne DH et al. Macrocytosis is a common occurrence in hemodialysis patients chronically receiving recombinant erythropoietin (EPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:12. Abstract.

95. Mohini R, Michaels R, Trost C et al. Comparison of effect of recombinant human erythropoietin (rHuEPO) in patients on high flux (HF) versus conventional (C) hemodialysis. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:13. Abstract.

96. Nissenson AR, Marsh JT, Brown WS et al. Brain function improves in chronic hemodialysis (CHD) patients (pts) after recombinant erythropoietin (rEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:13. Abstract.

97. Quinn P, Acchiardo S, Cockrell S et al. Response to erythropoietin (EPO) in patients (pts) on conventional (CD) and high flux dialysis (HF). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:15. Abstract.

98. Schaefer RM, Kokot F, Heidland A. Impact of recombinant human erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol. 1989; 76:273-82. [PubMed 2684527]

99. Shinaberger JH, Miller JH, Gardner PW et al. Disadvantages and risks of normal hematocrit (HCT) hemodialysis (HD). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:15. Abstract.

100. Valderrabano F. Adverse drug effects of recombinant human erythropoietin (rHuEPO). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:15. Abstract.

101. Van Wyck DB, Stivelman J, Kirlin L et al. Predicting iron status in patients receiving erythropoietin for dialysis- associated anemia. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:16. Abstract.

102. Wolcott DL, Schweitzer S, Nissenson AR. Recombinant erythropoietin (rEPO) improves cognitive function (CF) and quality of life (QL) of chronic hemodialysis (CHD) patients (Pts). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:16. Abstract.

103. Macdougall IC, Coles GA, Williams JD. The pharmacokinetics of recombinant erythropoietin in CAPD patients. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11- 14, 1988. Thorofare, NJ: Special Projects Network; 1988:17. Abstract.

104. Jamgotchian N, Hu MS, Abdella P et al. Recombinant human erythropoietin (rHuEPO)-induced hypertension (HPT): development of an experimental model. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:18. Abstract.

105. Mayer G, Cada EM, Watzinger U et al. Pathophysiology of hypertension in dialysis patients treated with erythropoietin. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11- 14, 1988. Thorofare, NJ: Special Projects Network; 1988:18. Abstract.

106. Prior JE, Terzian A, Schwartz AB et al. Prolonged RBC survival and hematopoietic response to recombinant human erythropoietin (rHuEPO) in chronic renal failure (CRF). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:19. Abstract.

107. Stockenhuber F, Geissler K, Sunder-Plassmann G et al. Recombinant human erythropoietin (rHuEPO) activates a broad spectrum of hematopoietic stem cells. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:19. Abstract.

108. Grutzmacher P, Radtke HW, Stahl RAK et al. Renal artery stenosis and erythropoietin. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:20. Abstract.

109. Schwartz AB, Mintz GS, Kim KE et al. Recombinant human erythropoietin (rHuEPO) increases MAP, TPRI and systolic and diastolic dysfunction with increased impedance to LV ejection due to increased HCT and RBC mass in pts with CRF. Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:20. Abstract.

110. Riedel E, Hampl H, Nundel M et al. Correction of amino acid (AA) metabolism by recombinant human erythropoietin (rHuEPO) in hemodialized patients (HD). Abstracts on recombinant erythropoietin from the American Society of Nephrology 21st annual meeting, San Antonio, TX, December 11-14, 1988. Thorofare, NJ: Special Projects Network; 1988:21. Abstract.

111. Ogden DA. Introduction. Semin Nephrol. 1989; 9(Suppl 2):1-2.

112. Van Stone JC. Who should receive recombinant human erythropoietin? Semin Nephrol. 1989; 9(Suppl 2):3-7.

113. Stivelman JC. Resistance to recombinant human erythropoietin therapy; a real clinical entity? Semin Nephrol. 1989; 9(Suppl 2):8-11.

114. Ogden DA. Monitoring considerations in recombinant human erythropoietin therapy. Semin Nephrol. 1989; 9(Suppl 2):12-5. [PubMed 2669080]

115. Levin N. Management of blood pressure changes during recombinant human erythropoietin therapy. Semin Nephrol. 1989; 9(Suppl 2):16-20. [PubMed 2669081]

116. Van Wyck DB. Iron deficiency in patients with dialysis- associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Nephrol. 1989; 9(Suppl 2):21-4. [PubMed 2669082]

117. Nissenson AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol. 1989; 9(Suppl 2):25-31. [PubMed 2669083]

118. Casati S, Campise M, Ponticelli C. Erythropoietin concentrations during treatment. Lancet. 1989; 1:1078. [IDIS 254612] [PubMed 2566024]

119. Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989; 321:158-63. [IDIS 257078] [PubMed 2747747]

120. Sasaki H, Bothner B, Dell A et al. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem. 1987; 262:12059-76. [PubMed 3624248]

121. Recny MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. J Biol Chem. 1987; 262:17156-63. [PubMed 3680293]

122. Anon. Erythropoietin for anemia. Med Lett Drugs Ther. 1989; 31:85-86. [PubMed 2671624]

123. Spivak JL, Barnes DC, Fuchs E et al. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA. 1989; 261:3104-07. [PubMed 2716142]

124. Walker RE, Parker RI, Kovacs JA et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med. 1988; 108:372-376. [IDIS 239619] [PubMed 3422548]

125. Summerfield GP, Bellingham AJ. The effects of therapeutic dialysis and renal transplantation on uraemic serum inhibitors of erythropoiesis in vitro. Br J Haematol. 1984; 58:293-304.

126. Sawada K, Krantz SB, Kans JS et al. Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest. 1987; 80:357-366. [PubMed 3038955]

127. Rosenlöf K, Fyhrquist F, Pekonen F. Receptors for recombinant erythropoietin in human bone marrow cells. Scand J Clin Lab Invest. 1987; 47:823-827. [PubMed 2829343]

128. Graf H, Mayer G, Cada E et al. Correction of anemia by recombinant human erythropoietin (r-HuEPO) enhances working capacity and exercise tolerance in patients on chronic hemodialysis. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:2.

129. Paganini E, Garcia J, Ellis P et al. Clinical sequelae of correction of anemia with recombinant human erythropoietin (r- HuEPO): urea kinetics, dialyzer function and reuse. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:3.

130. Cheung JY, Scaduto RC Jr, Tilotson DL et al. Mechanism of action of erythropoietin (EPO): a single cell study. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:4.

131. Bocker A, Reimers E, Nonnast-Daniel B et al. Effect of erythropoietin (EPO) treatment on hemoglobin O2-affinity and physical performance in patients with renal anemia. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:5.

132. Robertson HT, Haley NR, Adamson JW et al. Increase in maximal exercise capacity in hemodialysis (HD) patients following correction of the anemia with recombinant human erythropoietin (r-HuEPO). Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:6.

133. Paganini E, Thomas T, Fouad F et al. The correction of anemia in hemodialysis patients using recombinant human erythropoietin (r-HuEPO): hemodynamic effects. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:7.

134. Lundin AP, Delano BG, Stein R et al. Recombinant human erythropoietin (r-HuEPO) treatment enhances exercise tolerance in hemodialysis patients (HD). Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:8.

135. Eschbach JW, Adamson JW. Correction of the anemia of hemodialysis (HD) patients with recombinant human erythropoietin (r-HuEPO): results of multicenter study. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:9.

136. Van Stone JC, Jones ME, Hires CE. A controlled study of recombinant erythropoietin (EPO) in chronic hemodialysis patients. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:10.

137. Nissenson AR, Marsh JT, Brown WS et al. Recombinant erythropoietin (r-HuEPO) improves brain function in chronic hemodialysis (CHD) patients (PTS). Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:11.

138. Hampl H, Riedel E, Wendel G et al. Influence of parathyroid hormone (PTH) on exogenous erythropoietin (EPO) stimulated erythropoiesis in hemodialysis (HD) patients. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:12.

139. Delano BG, Lundin AP, Galonsky R et al. Dialyzer urea and creatinine clearances not significantly changed in r-HuEPO treated maintenance hemodialysis (MD) patients. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:13.

140. Bargman JM, Breborowicz A, Rodela H et al. Absorption of recombinant human erythropoietin (r-HuEPO) from the peritoneal cavity in rabbits. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:14.

141. Sun CH, Paul W, Ward HJ et al. Erythropoiesis and radioimmunoassayable recombinant human erythropoietin (r-HuEPO) in renal transplant (Tx) recipients. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:15.

142. Brown CD, Kieran M, Dosunmu BV et al. Raised hematocrit (HCT) persists six-weeks after stopping treatment with human recombinant erythropoietin (r-HuEPO) in azotemic, anemic patients. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:16.

143. Brown CD, Kieran M, Zhao ZH et al. Treatment of azotemic, anemic patients with human recombinant erythropoietin (r-HuEPO) raises whole blood viscosity (WBV) proportional to hematocrit (HCT). Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:17.

144. Van Wyck DB, Stivelman J, Ruiz J et al. Aluminum excess poses modest resistance to recombinant human erythropoietin (r- HuEPO) for dialysis anemia. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:18.

145. Wolcott DL, Schweitzer S, Marsh JT et al. Recombinant erythropoietin (r-HuEPO) improves cognitive function (CF) and quality of life (QL) of chronic hemodialysis (CHD) patients (PTS). Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13- 16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:19.

146. Zehnter E, Pollok M, Longere F et al. Urea kinetics (UK) in patients on RDT treated with recombinant erythropoietin (EPO). Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13- 16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:20.

147. Egrie JC, Eschbach JW, McGuire T et al. Pharmacokinetics of recombinant human erythropoietin (r-HuEPO) administered to hemodialysis (HD) patients. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:21.

148. Stivelman J, Van Wyck D, Kirlin L et al. Use of recombinant erythropoietin (r-HuEPO) with high efficiency dialysis (HED) does not worsen azotemia or shorten access survival. Selected abstracts on recombinant erythropoietin from the American Society of Nephrology 20th annual meeting, December 13-16, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:22.

149. Miller BA, Scaduto RC Jr, Tilotson DL et al. Erythropoietin and GM-CSF stimulate a rise in intracellular free calcium concentraction [Cacm] in single early human erythroid precursors at specific stages of differentiation. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:8.

150. Sawyer ST, Sawada K, Krantz SB. Structure of the receptor for erythropoietin in murine and human erythroid cells and murine placenta. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:16.

151. Lacombe C, Bruneval P, Da Silva JL et al. Expression of the erythropoietin gene in the hypoxic adult mouse. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:29.

152. Dubé S, Lin N, Manger R et al. Erythropoietin (EPO) requires specific addition of carbohydrate (CHO) side chains for intracellular processing and secretion. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:39.

153. Reid CDL, Fidler J, Wine.dtd CG et al. The response of erythroid progenitors to administered recombinant human erythropoietin in hemodialysed renal failure patients. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:48.

154. Means RT, Olsen NJ, Krantz SB et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro results. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:50.

155. McMahon RG, Ryan M, Phillips JH Jr et al. Safety and multiple dose pharmcokinetic profile of intravenous and subcutaneous recombinant human erythropoietin (r-HuEPO) in normal subjects: a double-blind, placebo controlled study. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:52.

156. Mannucci PM, Moia M, Casati S et al. Recombinant human erythropoietin (r-HuEPO) improves hemostatic abnormalities in uremics. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:52.

157. Al-Khatti A, Fritsch E, Papayannopoulou T et al. Erythropoietin stimulates fetal hemoglobin in macaques and produces an additive Hb F induction in baboons treated with hydroxyurea. Selected abstracts on hematopoietic growth factors from the American Society of Hematology 29th annual meeting, December 5-8, 1987, Washington, DC. Thorofare, NJ: Special Projects Network; 1988:60.

158. Martin W, Villani GM, Jothianandan D et al. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. 1985; 232:708-16. [PubMed 2983068]

159. Laver J, Moore MAS. Clinical use of recombinant human hematopoietic growth factors. J Natl Cancer Inst. 1989; 81:1370-82. [IDIS 259267] [PubMed 2674457]

160. Cotes PM, Pippard MJ, Reid CDL et al. Continuing correction of anaemia by treatment with recombinant erythropoietin in patients maintained by haemodialysis. Exp Hematol. 1987; 15:437.

161. Goodnough LT, Rudnick S, Price TH et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989; 321:1163-8. [IDIS 259994] [PubMed 2677725]

162. Drüeke T, Zins B, Naret C et al. Erythropoietin and chronic renal failure. Nouv Rev Fr Hematol. 1989; 31:97-8. [PubMed 2771635]

163. Krane NK. The role of erythropoietin in the anemia of renal failure. Henry Ford Hosp Med J. 1983; 31:177-81. [PubMed 6358139]

164. Wang FF, Kung CKH, Goldwasser E. Some chemical properties of human erythropoietin. Endocrinology. 1985; 116:2286-92. [PubMed 3996312]

165. Yoshimura N, Oka T, Ohmori Y et al. The effects of recombinant human erythropoietin on the anemia of renal transplant recipients with chronic rejection. Transplantation. 1989; 48:527-9. [PubMed 2675414]

166. Ponticelli C, Casati S. Correction of anaemia with recombinant human erythropoietin. Nephron. 1989; 52:201-8. [PubMed 2662045]

167. Sawyer ST. The two proteins of the erythropoietin receptor are structurally similar. J Biol Chem. 1989; 264:13343-7. [PubMed 2546955]

168. Ganser A, Bergmann M, Völkers B et al. In vivo effects of recombinant human erythropoietin on circulating human hemopoietic progenitor cells. Exp Hematol. 1989; 17:433-5. [PubMed 2714423]

169. Fukuda MN, Sasaki H, Lopez L et al. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood. 1989; 73:84-9. [PubMed 2910371]

170. Sytkowski AJ, Donahue KA. Immunochemical studies of human erythropoietin using site-specific anti-peptide antibodies: identification of a functional domain. J Biol Chem. 1987; 262:1161-5. [PubMed 2433274]

171. Erslev AJ. Renal biogenesis of erythropoietin. Am J Med. 1975; 58:25-30. [PubMed 1090149]

172. Baer AN, Dessypris EN, Goldwasser E et al. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol. 1987; 66:559-64. [PubMed 3663512]

173. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111:992-1000. [IDIS 261615] [PubMed 2688507]

174. Eckardt KU, Bauer C. Erythropoietin in health and disease. Eur J Clin Invest. 1989; 19:117-27. [PubMed 2499469]

175. Anagnostou A. Erythropoietin: a hematopoietic hormone produced by the kidney. Semin Nephrol. 1985; 5:104-14. [PubMed 3843784]

176. Goldwasser E. Erythropoietin and the differentiation of red blood cells. Fed Proc. 1975; 34:2285-92. [PubMed 172374]

177. Caro J, Brown S, Miller O et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979; 93:449-58. [PubMed 570997]

178. Fisher JW. Extrarenal erythropoietin production. J Lab Clin Med. 1979; 93:695-9. [PubMed 372468]

179. Radtke HW, Erbes PM, Schippers E et al. Serum erythropoietin concentration in anephric patients. Nephron. 1978; 22:361-5. [PubMed 740098]

180. Wideröe TE, Sanengen T, Halvorsen S. Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis. Kidney Int. 1983; 24(Suppl 16):S208-17.

181. Pavlovic-Kentera V, Ruvidic R, Milenkovic P et al. Erythropoietin in patients with anaemia in rheumatoid arthritis. Scand J Haematol. 1979; 23:141-5. [PubMed 493876]

182. Krantz SB, Sawada KI, Sawyer ST et al. Specific binding of erythropoietin to human erythroid colony-forming cells. Trans Assoc Am Physicians. 1987; 100:164-72. [PubMed 2842914]

183. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985; 82:7580-4. [PubMed 3865178]

184. Davis JM, Arakawa T, Strickland TW et al. Characterization of recombinant human erythropoietin produced in chinese hamster ovary cells. Biochemistry. 1987; 26:2633-8. [PubMed 3607040]

185. Sasaki H, Ochi N, Dell A et al. Site-specific glycosylation of recombinant human erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry. 1988; 27:8618-26. [PubMed 3219367]

186. Steinhauer HB, Lubrich-Birkner I, Dreyling KW et al. Increased ultrafiltration after erythropoietin-induced correction of renal anemia in patients on continuous ambulatory peritoneal dialysis. Nephron. 1989; 53:91-2. [PubMed 2779711]

187. Flaharty KK, Grimm AM, Vlasses PH. Epoetin: recombinant human erythropoietin. Clin Pharm. 1989; 8:769-82. [IDIS 261096] [PubMed 2680241]

188. Schuster SJ, Caro J, Erslev AJ. Erythropoietin: current concepts and future prospects. Hematol Pathol. 1987; 1:193-201. [PubMed 3332878]

189. Canaud B, Donadieu P, Polito C et al. Erythropoietin- associated hypertension: what role for blood viscosity changes? Nephron. 1989; 51:430-1. Letter.

190. Peschle C. Erythropoiesis. Ann Rev Med. 1980; 31:303-14. [PubMed 6249187]

191. Sytkowski AJ, McIntyre CJ, Perrine SP et al. The biochemistry of erythropoietin: an approach to its mode of action. Exp Hematol. 1980; 8(Suppl 8):52-64. [PubMed 6962071]

192. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood. 1982; 60:1241-6. [PubMed 6753967]

193. Dessypris EN, Gleaton JH, Armstrong O. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol. 1987; 65:265-9. [PubMed 3567081]

194. Meytes D, Bogin E, Ma A et al. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981; 67:1263-9. [PubMed 7229028]

195. Graber SE, Krantz SB. Erythropoietin and the control of red cell production. Ann Rev Med. 1978; 29:51-66. [PubMed 206191]

196. McGonigle RJ, Wallin JD, Shadduck RK et al. Erythropoietin deficiency and the inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984; 25:437-44. [PubMed 6727139]

197. Lee-Huang S. Cloning and expression of human erythropoietin cDNA in Escherichia coli. Proc Natl Acad Sci USA. 1984; 81:2708-12. [PubMed 6371819]

198. Sue JM, Sytkowski AJ. Site-specific antibodies to human erythropoietin directed toward the NH2-terminal region. Proc Natl Acad Sci USA. 1983; 80:3651-5. [PubMed 6190179]

199. Ziegler J. Growth factors, act II: movement into and through clinical trials. J Natl Cancer Inst. 1989; 81:888-90. [PubMed 2659800]

200. Kindler J, Eckardt KU, Ehmer B et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant. 1989; 4:345-9. [PubMed 2505184]

201. Shinaberger JH, Miller JH, Gardner PW. Erythropoietin alert: risks of high hematocrit hemodialysis. ASAIO Trans. 1988; 34:179-84. [PubMed 3196506]

202. Caro J, Erslev AJ. Uremic inhibitors of erythropoiesis. Semin Nephrol. 1985; 5:128-32. [PubMed 3879951]

203. Löw I, Grützmacher P, Bergmann M et al. Electrocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol. 1989; 31:26-30. [PubMed 2521587]

204. Berridge MV, Fraser JK, Carter JM et al. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood. 1988; 72:970-7. [PubMed 3416080]

205. Dessypris EN, Graber SE, Krantz SB et al. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood. 1988; 72:2060-2. [PubMed 3196879]

206. Egrie JC, Strickland TW, Lane J et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 1986; 172:213-24. [PubMed 3542810]

207. Donahue RE, Johnson MM, Zon LI et al. Suppression of in vitro haematopoiesis followng human immunodeficiency virus infection. Nature. 1987; 326:200-3. [PubMed 2434864]

208. Segal GM, Eschbach JW, Egrie JC et al. The anemia of end-stage renal disease: hematopoietic progenitor cell response. Kidney Int. 1988; 33:983-8. [PubMed 3392887]

209. Pascual J, Liano F, Matesanz R et al. Recombinant human erythropoietin treatment in patients on maintenance home haemodialysis. Lancet. 1989; 2:160. [IDIS 257213] [PubMed 2567923]

210. Erslev AJ, Caro J. Physiologic and molecular biology of erythropoietin. Med Oncol Tumor Pharmacother. 1986; 3:159-64. [PubMed 3543529]

211. Maeda H, Hitomi Y, Hirata R et al. Erythropoietin and autologous blood donation. Lancet. 1989; 2:284. [IDIS 258278] [PubMed 2569098]

212. Wahlberg J, Jacobsson J, Odlind B et al. Haemodilution in renal transplantation in patients on erythropoietin. Lancet. 1988; 2:1418. [PubMed 2904536]

213. Miller BA, Cheung JY, Tillotson DL et al. Erythropoietin stimulates a rise in intracellular-free calcium concentration in single BFU-E derived erythroblasts at specific stages of differentiation. Blood. 1989; 73:1188-94. [PubMed 2649170]

214. Schaefer RM, Leschke M, Strauer BE et al. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol. 1988; 8:449-53. [PubMed 3218658]

215. Levine EA, Rosen AL, Sehgal LR et al. Treatment of acute postoperative anemia with recombinant human erythropoietin. J Trauma. 1989; 29:1134-9. [PubMed 2760953]

216. Fried W, Morley C. Update on erythropoietin. Int J Artif Organs. 1985; 8:79-82. [PubMed 3886559]

217. Hoshino S, Teramura M, Takahashi M et al. Expression and characterization of erythropoietin receptors on normal human bone marrow cells. Int J Cell Cloning. 1989; 7:156-67. [PubMed 2543713]

218. McGonigle RJS, Husserl F, Wallin JD et al. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int. 1984; 25:430-6. [PubMed 6727138]

219. Levine EA, Gould SA, Rosen RL et al. Perioperative recombinant human erythropoietin. Surgery. 1989; 106:432-8. [PubMed 2763040]

220. Grützmacher P, Scheuermann E, Löw I et al. Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol. 1988; 66:176-84. [PubMed 3292146]

221. Burghard R, Leititis J, Pallacks R et al. Treatment of a seven-year-old child with end-stage renal disease and hemosiderosis by recombinant human erythropoietin. Contrib Nephrol. 1988; 66:139-48. [PubMed 3391028]

222. Wine.dtd CG. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin. Drugs. 1989; 3:342-5.

223. Kurtz A, Eckardt KU, Tannahill L et al. Regulation of erythropoietin production. Contrib Nephrol. 1988; 66:1- 16. [PubMed 3391025]

224. Bommer J, Huber W, Tewes G et al. Treatment of polytransfused hemodialysis patients with recombinant human erythropoietin. Contrib Nephrol. 1988; 66:131-8. [PubMed 3391027]

225. Bommer J, Kugel M, Schoeppe W et al. Dose-related effects of recombinant human erythropoietin on erythropoiesis: results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol. 1988; 66:85-93. [PubMed 3292151]

226. Hirth P, Wieczorek L, Scigalla P. Molecular biology of erythropoietin. Contrib Nephrol. 1988; 66:38-53. [PubMed 3391033]

227. Samtleben W, Baldamus CA, Bommer J et al. Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol. 1988; 66:114-22. [PubMed 3292144]

228. Grützmacher P, Bergmann M, Weinreich T et al. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol. 1988; 66:104-13. [PubMed 3292143]

229. Kühn K, Nonnast-Daniel B, Grützmacher P et al. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Contrib Nephrol. 1988; 66:94-103. [PubMed 3292152]

230. Lipkin GW, Kendall R, Haggett P et al. Erythropoietin in acute renal failure. Lancet. 1989; 1:1029. [PubMed 2565512]

231. McCarthy JT, Johnson WJ, Nixon DE et al. Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy. J Lab Clin Med. 1989; 114:193-9. [IDIS 307517] [PubMed 2754306]

232. Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med. 1987; 109:429-33. [PubMed 3102659]

233. Nielsen OJ, Thaysen JH. Response to erythropoietin in anaemic haemodialysis patients. J Intern Med. 1989; 226:89-94. [IDIS 300465] [PubMed 2671248]

234. Hino M, Miyazono K, Urabe A et al. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodilysis patients in vitro and in vivo. Int J Cell Cloning. 1989; 7:257-62. [PubMed 2768843]

235. Urabe A, Saito T, Fukamachi H et al. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states. Int J Cell Cloning. 1987; 5:202-8. [PubMed 3598244]

236. Spivak JL. The mechanism of action of erythropoietin. Int J Cell Cloning. 1986; 4:139-66. [PubMed 3009649]

237. Pavlovic-Kentera V, Clemons GK, Djukanovic L et al. Erythropoietin and anemia in chronic renal failure. Exp Hematol. 1987; 15:785-9. [PubMed 3609182]

238. Shimizu T, Miyake T, Pilch AM et al. Biochemical properties of human urinary megakaryocyte colony-stimulating factor and erythropoietin: the role of sulfhydryl groups and disulfide bonds. Exp Cel Biol. 1986; 54:281-6.

239. Zanjani ED, Ascensao JL. Erythropoietin. Transfusion. 1989; 29:46-57. [PubMed 2643210]

240. van Geet C, Hauglustaine D, Verresen L et al. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost. 1989; 61:117-21. [PubMed 2749585]

241. Broudy VC, Tait JF, Powell JS. Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. Arch Biochem Biophys. 1988; 265:329-36. [PubMed 3421710]

242. Hochberg MC, Arnold CM, Hogans BB et al. Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. Arthritis Rheum. 1988; 31:1318-21. [PubMed 3178910]

243. Schmidt B, Ward RA. The impact of erythropoietin on hemodialyzer design and performance. Artif Organs. 1989; 13:35-42. [PubMed 2712734]

244. Paganini EP, Latham D, Abdulhadi M. Practical considerations of recombinant human erythropoietin therapy. Am J Kidney Dis. 1989; 14(Suppl 1):19-25. [PubMed 2667348]

245. Eschbach JW, Adamson JW. Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis. 1989; 14(Suppl 1):2-8. [PubMed 2667349]

246. Kurtz A. Erythropoietin: structure, function, origin. Adv Nephrol. 1987; 16:371-8.

247. Ad Hoc Committee for the National Kidney Foundation. Statement on clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Am J Kidney Dis. 1989; 14:163-9. [PubMed 2672796]

248. Chandra M, Clemons GK, McVicar M et al. Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis. Am J Kidney Dis. 1988; 12:208-13. [PubMed 3414676]

249. Jelkmann W. Renal erythropoietin: properties and production. Rev Physiol Biochem Pharmacol. 1986; 104:139-215. [PubMed 3520776]

250. Remuzzi G. Bleeding in renal failure. Lancet. 1988; 1:1205-8. [IDIS 242952] [PubMed 2897015]

251. Johnson CA. Epoetin alfa: a therapeutic achievement from pharmaceutical biotechnology. US Pharmacist. 1989; Nov:H1-22.

252. Krantz SB, Sawyer ST, Sawada KI. Purification of erythroid progenitor cells and characterization of erythropoietin receptors. Br J Cancer. 1988; 58(Suppl 9):31-5.

253. Dubé S, Fischer JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem. 1988; 263:17516-21. [PubMed 3182860]

254. Takeuchi M, Takasaki S, Miyazaki H et al. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant chinese hamster ovary cells. J Biol Chem. 1988; 263:3657-63. [PubMed 3346214]

255. Krumweih D, Arnold I, Seiler FR. Biological characterization of recombinant human erythropoietin. Behring Inst Mitt. 83:193-201.

256. Binkley L, Gallagher N, Lathan D et al. Epoetin alfa: a keystone in the treatment of the anemic patient with chronic renal failure. ANNA J. 1989; 16:341-51. [PubMed 2673076]

257. Lamperi S, Carozzi S, Icardi A et al. Pathogenesis of uremic anemia and new therapeutic prospectives. Contrib Nephrol. 1989; 69:190-4. [PubMed 2661141]

258. Goldwasser E. The action of erythropoietin as the inducer of erythroid differentiation. Prog Clin Biol Res. 1985; 184:77-84. [PubMed 2996019]

259. Egrie JC, Browne J, Lai P et al. Characterization of recombinant monkey and human erythropoietin. Prog Clin Biol Res. 1985; 191:339-50. [PubMed 2996025]

260. Pagel H, Jelkmann W, Weiss C. Erythropoietin and blood pressure. Horm Metab Res. 1989; 21:224. [PubMed 2753475]

261. Gurland HJ, Samtleben W, Schmidt B. Effect of erythropoietin administration in uremia. Contrib Nephrol. 1989; 70:172-7. [PubMed 2670428]

262. Lai PH, Everett R, Wang FF et al. Structural characterization of human erythropoietin. J Biol Chem. 1986; 261:3116-21. [PubMed 3949763]

263. Macdougall IC, Hutton RD, Cavill I et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989; 299:157-8. [IDIS 257253] [PubMed 2504356]

264. Baciu I, Ivanof L. Erythropoietin interaction with the mature red cell membrane. Ann NY Acad Sci. 1983; 414:66-72. [PubMed 6322655]

265. Brown AL, Tucker B, Baker LRI et al. Seizures related to blood transfusion and erythropoietin treatment in patients undergoing dialysis. BMJ. 1989; 299:1258-9. [IDIS 261039] [PubMed 2513901]

266. Temple RM, Eadington DW, Swainson CP et al. Seizure related to erythropoietin treatment in patients undergoing dialysis. Br Med J. 1990; 300:46.

267. Najean Y, Moynot A, Deschryver F et al. Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin treatment. Nephrol Dial Transplant. 1989; 4:350-5. [PubMed 2505185]

268. Browne JK, Cohen AM, Egrie JC et al. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol. 1986; 51(Part 1):693- 702. [PubMed 3472747]

269. Massry SG. Pathogenesis of the anemia of uremia: role of secondary hyperparathyroidism. Kidney Int. 1983; 24(Suppl 16):S204-7. [PubMed 6620852]

270. Yoshida Y, Ohmori S, Tohyama K et al. Erythropoietic changes in chronic hemodialysis patients undergoing recombinant human erythropoietin therapy. Acta Haematol JPN. 1988; 51:1092-6.

271. Adamson JW. Erythropoietin: in vitro and in vivo studies of the regulation of erythropoiesis. Schweiz Med Wochenschr. 1988; 118:1501-6. [PubMed 2849202]

272. London GM, Zins B, Pannier B et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int. 1989; 36:878-882. [PubMed 2615194]

273. Stockenhuber F, Kurz RW, Geissler K et al. Recombinant human erythropoietin activates a broad spectrum of progenitor cells. Kidney Int. 1990; 37:150-6. [PubMed 2299802]

274. Lim VS, Fangman J, Flanigan MJ et al. Effect of recombinant human erythropoietin on renal function in humans. Kidney Int. 1990; 37:131-6. [PubMed 2299799]

275. Riedel E, Nündel M, Algermissen B et al. Changes in the concentrations of hydroxyproline, glycine and serine in the plasma of haemodialysis patients undergoing erythropoietin therapy. J Clin Chem Clin Biochem. 1989; 27:851-6. [PubMed 2514250]

276. Acchiardo SR, Quinn BP, Burk LB et al. Are high flux dialysis and erythropoietin treatment in a collision course? ASAIO Trans. 1989; 35:308-10.

277. Paganini EP, Abdulhadi MH, Garcia J et al. Recombinant human erythropoietin correction of anemia: dialysis efficiency, waste retention, and chronic dose variables. ASAIO Trans. 1989; 35:513-5. [PubMed 2688718]

278. Wolcott DL, Marsh JT, LaRue A et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis. 1989; 14:478-85. [PubMed 2596475]

279. Kleinman KS, Schweitzer SU, Perdue ST et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double- blind, placebo-controlled trial. Am J Kidney Dis. 1989; 14:486-95. [PubMed 2688405]

280. Lim VS, Kirchner PT, Fangman J et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis. 1989; 14:496-506. [PubMed 2596476]

281. Evans RW, Rader B, Manninen DL et al. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990; 263:825-30. [IDIS 262542] [PubMed 2404150]

282. Anderson KE, Goeger DE, Carson RW et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med. 1990; 322:315-7. [IDIS 262681] [PubMed 2104958]

283. Canaud B, Polito-Bouloux C, Garred LJ et al. Recombinant human erythropoietin: 18 months’ experience in hemodialysis patients. Am J Kidney Dis. 1990; 15:169-75. [PubMed 2301388]

284. Imagawa A, Kawanishi Y, Numata A. Is erythropoietin effective for impotence in dialysis patients? Nephron. 1990; 54:95-6. Letter.

285. Moynot A, Zins B, Naret C et al. Traitement pendant un an de 42 malades hémodialysés chroniques par l’erythropoïétine recombinante humaine. (French; with English abstract.) Presse Med. 1990; 19:111-5.

286. Spivak J. Erythropoietin: a new paradigm. J Lab Clin Med. 1990; 115:10-1. [PubMed 2405079]

287. Nielsen OJ, Thaysen JH. Vital indication for erythropoietin in a chronic haemodialysis patient: a case report. Dan Med Bull. 1989; 36:590-2. [PubMed 2612227]

288. Oster W, Herrmann F, Cicco A et al. Erythropoietin prevents chemotherapy-induced anemia: case report. Blut. 1990; 60:88-92. [PubMed 2405925]

289. Lui SF, Chung WWM, Leung CB et al. Pharmacokinetics and pharmacoynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol. 1990; 33:47-51. [PubMed 2302870]

290. Satoh K, Masuda T, Ikeda Y et al. Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension. 1990; 15:262-6. [PubMed 2303284]

291. Besarab A, Girone JF, Erslev A et al. Recent developments in the anemia of chronic renal failure. Sem Dial. 1989; 2:87-97.

292. Vaziri ND, Ritchie C, Brown P et al. Effect of erythropoietin administration on blood plasma viscosity in hemodialysis patients. ASAIO Trans. 1989; 35:505-8. [PubMed 2597519]

293. Ortho Biotech Division. Eprex (r-HuEPO, Ortho): treatment program for anemia in AIDS patients. Protocol No. I88- 083. Raritan, NJ; 1989 May.

294. Ortho Biotech Division. Eprex (r-HuEPO) treatment program for anemia in AIDS patients. Anemia in AIDS patients: pathophysiology and therapy. Raritan, NJ: Ortho Pharmaceutical Corporation. 1989 May.

295. Macdougall IC, Lewis NP, Saunders MJ et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet. 1990; 1:489-93.

296. Heinz R, Reisner R, Pittermann E. Erythropoietin for chemotherapy patient refusing blood transfusion. Lancet. 1990; 1:542-3.

297. Ganser A, Volkers B, Scigalla P et al. Effect of human recombinant erythropoietin on human hematopoietic progenitor cells in vitro. Klin Wochenschr. 1988; 66:236-40. [PubMed 3367615]

298. Macdougall IC, Hutton RD, Cavill I et al. Treating renal anemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. Br Med J. 1990; 300:655-9.

299. Hambley H, Mufti GJ. Erythropoietin: an old friend revisited. Br Med J. 1990; 300:621-2.

300. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J. 1990; 300:573-8.

301. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977; 252:5558-64. [PubMed 18467]

302. Lundin AP, Delano BG, Quinn-Cefaro R. Perspectives on the improvement of quality of life with epoetin alfa therapy. Pharmacotherapy. 1990; 10(2 Part 2):22-6S.

303. Krantz SB. Review of patients’ responses to epoetin alfa therapy. Pharmacotherapy. 1990; 10(2 Part 2):15-21S. [PubMed 2179899]

304. Flaharty KK. Clinical pharmacology of recombinant human erythropoietin (r-HuEPO). Pharmacotherapy. 1990; 10(2 Part 2):9-14S.

305. Egrie J. The cloning and production of recombinant human erythropoietin. Pharmacotherapy. 1990; 10(2 Part 2):3- 8S.

306. Cotton SL, Holchek MJ. Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis. ANNA J. 1989; 16:463-8. [PubMed 2604448]

307. Ganser A, Völkers B, Scigalla P et al. Effect of human recombinant erythropoietin on human hemopoietic progenitor cells in vitro. Klin Wochenschr. 1988; 66:236-40. [PubMed 3367615]

308. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood. 1989; 73:90-9. [PubMed 2462945]

309. Neumayer HH, Brockmöller J, Fritschka E et al. Pharmacokinetics of recombinant human erythropoietin after SC administration and long-term IV treatment in patients on maintenance hemodialysis. Contrib Nephrol. 1989; 76:131-42. [PubMed 2582778]

310. Kampf D, Kahl A, Passlick J et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Contrib Nephrol. 1989; 76:106-11. [PubMed 2582776]

311. Fukuda M, Sasaki H, Fukuda MN. Erythropoietin metabolism and the influence of carbohydrate structure. Contrib Nephrol. 1989; 76:78-89. [PubMed 2684536]

312. Samtleben W, Baldamus CA, Bommer J et al. Indications and contraindications for recombinant human erythropoietin treatment: results in hemodialysis patients. Contrib Nephrol. 1989; 76:193-200. [PubMed 2684521]

313. Macdougall IC, Cavill I, Davies ME et al. Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients. Contrib Nephrol. 1989; 76:219-26. [PubMed 2582780]

314. Fischer C, Scigalla P, Park W et al. Influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency. Contrib Nephrol. 1989; 76:250-6. [PubMed 2684526]

315. Nonnast-Daniel B, Schäffer J, Frei U. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin. Contrib Nephrol. 1989; 76:283-91. [PubMed 2684528]

316. Steffen HM, Brunner R, Müller R et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol. 1989; 76:292-8. [PubMed 2582783]

317. Kurtz A, Eckardt KU, Neumann R et al. Site of erythropoietin formation. Contrib Nephrol. 1989; 76:14- 23. [PubMed 2582779]

318. Goldwasser E. Regulation of erythropoietin gene expression. Contrib Nephrol. 1989; 76:2-6. [PubMed 2684522]

319. Lerche D, Schmidt R, Zoellner K et al. Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy. Contrib Nephrol. 1989; 76:299- 305. [PubMed 2684529]

320. Brunner R, Steffen HM, Pollok M et al. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin. Contrib Nephrol. 1989; 76:306-14. [PubMed 2582784]

321. Spivak JL. The in vivo metabolism of recombinant human erythropoietin. Contrib Nephrol. 1989; 76:67-77. [PubMed 2582785]

322. Koene RAP, Frenken LAM, Wetzels JFM et al. Treatment of predialysis patients with recombinant human erythropoietin. Contrib Nephrol. 1989; 76:242-49. [PubMed 2684525]

323. Scigalla P, Bonzel KE, Bulla M et al. Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol. 1989; 76:227- 41. [PubMed 2684524]

324. Pollok M, Bommer J, Gurland HJ et al. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients: results of a multicenter phase II/III study. Contrib Nephrol. 1989; 76:201-11. [PubMed 2684523]

325. Research Group for Clinical Assessment of rhEPO. Dose- finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Contrib Nephrol. 1989; 76:179-92. [PubMed 2684520]

326. Koury MJ, Koury ST, Bondurant MC et al. Correlation of the molecular and anatomical aspects of renal erythropoietin production. Contrib Nephrol. 1989; 76:24-32. [PubMed 2582781]

327. Kokot F, Wiecek A, Grzeszczak W et al. Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients. Contrib Nephrol. 1989; 76:257- 72. [PubMed 2582782]

328. Pousada L, Fiorito J, Smyth C. Erythropoietin and anemia of gastrointestinal bleeding in a Jehovah’s Witness. Ann Intern Med. 1990; 112:552. [IDIS 264388] [PubMed 2316946]

329. Nielsen OJ, Egfjord M, Hirth P. Erythropoietin metabolism in the isolated perfused rat liver. Contrib Nephrol. 1989; 76:90-7. [PubMed 2582786]

330. Birgergard G. Erythropoiesis and inflammation. Contrib Nephrol. 1989; 76:330-41. [PubMed 2684533]

331. Phibbs RH, Shannon K, Mentzer WC. Rationale for using recombinant human erythropoietin to treat the anemia of prematurity. Contrib Nephrol. 1989; 76:324-9. [PubMed 2684531]

332. Grützmacher P, Ehmer B, Messinger D et al. Effect of aluminum overload on the bone marrow response to recombinant human erythropoietin. Contrib Nephrol. 1989; 76:315-23. [PubMed 2684530]

333. Rosenlöf K, Fyhrquist F, Tenhunen R. Erythropoietin, aluminum, and anaemia in patients on haemodialysis. Lancet. 1990; 1:247.

334. Goodnough LT, Marcus RE. Erythropoietin and perioperative blood donation. N Engl J Med. 1990; 322:1158-9.

335. Fischl M, Galpin JE, Levine JD et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990; 322:1488-93. [IDIS 266352] [PubMed 2186273]

336. Beresford CH. Erythropoietin. New Zealand Med J. 1989; 102:185. [IDIS 270465] [PubMed 2652007]

337. Hughes RT, Cotes PM, Oliver DO et al. Correction of the anaemia of chronic renal failure with erythropoietin: pharmacokinetic studies in patients on haemodialysis and CAPD. Contrib Nephrol. 1989; 76:122-30. [PubMed 2582777]

338. Halpérin DS, Wacker P, Lacourt G et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr. 1990; 116:779- 86. [IDIS 267255] [PubMed 1691780]

339. Hoshino S, Teramura M, Takahashi M et al. Expression and characterization of erythropoietin receptors on normal human bone marrow cells. Int J Cell Cloning. 1989; 7:156-67. [PubMed 2543713]

340. Sawka MN, Young AJ, Muza SR et al. Erythrocyte reinfusion and maximal aerobic power: an examination of modifying factors. JAMA. 1987; 257:1496-9. [PubMed 3820465]

341. Williams MH, Wesseldine S, Somma T et al. The effect of induced erythrocythemia upon 5-mile treadmill run time. Med Sci Sports Exerc. 1981; 13:169-75. [PubMed 7253868]

342. Gledhill N. The influence of altered blood volume and oxygen transport capacity on aerobic performance. Exerc Sport Sci Rev. 1985; 13:75-93. [PubMed 3891376]

343. Kanstrup IL, Ekblom B. Blood volume and hemoglobin concentration as determinants of maximal aerobic power. Med Sci Sports Exerc. 1984; 16:256-62. [PubMed 6748923]

344. Flaharty KK, Caro J, Erslev A et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther. 1990; 47:557-64. [IDIS 267524] [PubMed 2188770]

345. Macdougall IC, Roberts DE, Neubert P et al. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD: a rationale for treatment. Contrib Nephrol. 1989; 76:112- 21. [PubMed 2684515]

346. Sobota JT. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease: US multicenter trials. Contrib Nephrol. 1989; 76:166-78. [PubMed 2684519]

347. Bommer J, Samtleben W, Koch KM et al. Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol. 1989; 76:149-58. [PubMed 2684517]

348. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990; 322:1689-92. [PubMed 2342534]

349. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990; 322:1693-9. [IDIS 267045] [PubMed 2342535]

350. Shannon KM, Naylor GS, Torkildson JC et al. Circulating erythroid progenitors in the anemia of prematurity. N Engl J Med. 1987; 317:728-33. [PubMed 3627181]

351. Renal diseases. In: Wyngaarden JB, Smith LH Jr, eds. Cecil textbook of medicine. 18th ed. Philadelphia: W.B. Saunders Company; 1988:438-597,2332.

352. Chandra M, Miller ME, Garcia JF et al. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron. 1985; 39:26-9. [PubMed 3969187]

353. Danko J, Huch R, Huch A. Epoetin alfa for the treatment of postpartum anemia. Lancet. 1990; 1:737-8.

354. McCluskey P, Kearns M, Taylor F et al. Coats’ type retinitis pigmentosa and subretinal neovascularisation in a patient with renal failure. Lancet. 1989; 2:1401. [PubMed 2574347]

355. Annable L, Cotes PM, Mussett MV. The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull World Health Organ. 1972; 47:99-112. [PubMed 4538911]

356. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology. 1985; 116:2293-99. [PubMed 3996313]

357. Anon. USAN Council: New names (list no. 316). Clin Pharmacol Ther. 1990; 47:667.

358. Wood P, Nygaard S, Hrushesky WJM. Cisplatin-induced anemia is correctable with erythropoietin. Blood. 1988; 72(Suppl):52a.

359. Bray GL, Reaman GH. Partial deficiency of erythropoietin (EPO) resulting from cisplatin (CPDD) mediated nephrotoxicity. Blood. 1988; 72(Suppl):37a.

360. Rosse W, Waldmann TA. The metabolism of erythropoietin in patients with anemia due to deficient erythropoiesis. J Clin Invest. 1964; 43:1348-54. [PubMed 14192515]

361. Al-Khatti A, Veith RW, Papayannopoulou T et al. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med. 1987; 317:415-20. [PubMed 2441258]

362. Martin J, Moncada S. Blood pressure, erythropoietin, and nitric oxide. Lancet. 1988; 2:644. [IDIS 245710] [PubMed 2901517]

363. Anon. EDRF. Lancet. 1987; 2:137-8. [PubMed 2885601]

364. Goldberg MA, Brugnara C, Dover GJ et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 1990; 323:366-72. [IDIS 269366] [PubMed 1695325]

365. Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus- infected erythroid cells. J Biol Chem. 1987; 262:5554- 62. [PubMed 3032937]

366. Amgen. Epogen (epoetin alfa) product monograph. Thousand Oaks, CA; 1989 Sept.

367. Mintz PD, Popovsky MA, Ness P. Erythropoietin and perioperative blood donation. Lancet. 1990; 1:1157-8.

368. Bell K, Gillon J. Erythropoietin and perioperative blood donation. Lancet. 1990; 1:1158.

369. Hennigan T. Erythropoietin and perioperative blood donation. Lancet. 1990; 1:1158.

370. Couch P, Stumpf JL. Management of uremic bleeding. Clin Pharm. 1990; 9:673-81. [IDIS 271195] [PubMed 2171866]

371. Thomas M, Saker BM, Thatcher GN et al. Cost- effectiveness of weekly and fortnightly subcutaneous erythropoietin. Lancet. 1990; 1:1533-4.

372. Martin GR, Ongkingco RJ, Turner ME et al. Short term effects of r-erythropoietin (EPO-Epogen) on cardiac performance. Am J Cardiol. 1990; 66:522.

373. Pincus T, Olsen NJ, Russell IJ et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med. 1990; 89:161-8. [IDIS 270064] [PubMed 2200263]

374. Prata MM, Sousa FT, Barbas JM et al. Blood lipids in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant. 1990; 5:474. [PubMed 2122328]

375. Widness JA, Malone TA, Mufson RA. Impermeability of the ovine placenta to35S-recombinant erythropoietin. Pediatr Res. 1989; 25:649-51. [PubMed 2740156]

376. Koury MJ, Bondurant MC, Graber SE et al. Erythropoietin messenger RNA levels in developing mice and transfer of125I-erythropoietin by the placenta. J Clin Invest. 1988; 82:154-9. [PubMed 3392205]

377. Graf H, Watzinger U, Ludvik B et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. Br Med J. 1990; 300:1627-8.

378. Koppensteiner R, Stockenhuber F, Jahn C et al. Changes in determinants of blood rheology during treatment with haemodialysis and recombinant human erythropoietin. Br Med J. 1990; 300:1626-7.

379. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327:524-6. [PubMed 3495737]

380. Martin W, Smith JA, White DG. The mechanisms by which haemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor. Br J Pharmacology. 1986; 89:563-71.

381. Skoglund RW, Finne PH. Renal tubular secretion of erythropoietin. Scand J Clin Lab Invest. 1972; 30:63-6. [PubMed 5073092]

382. Cowart VS. Erythropoietin: a dangerous new form of blood doping? Physician Sports Med. 1989; 17:115-8.

383. Davey RJ, Gallelli JF. Red cell transfusions to enhance athletic performance. Pharmacy Times. 1989; June:85-8.

384. Scott WC. The abuse of erythropoietin to enhance athletic performance. JAMA. 1990; 264:1660. [IDIS 271567] [PubMed 2398603]

385. Adamson JW, Vapnek D. Recombinant erythropoietin to improve athletic performance. N Engl J Med. 1991; 324:698-9. [IDIS 278565] [PubMed 1994258]

386. Anon. EPO potentially dangerous to athletes. Am Pharm. 1990; NS30:17-8.

387. Rothstein P, Roye D, Verdisco L et al. Preoperative use of erythropoietin in an adolescent Jehovah’s Witness. Anesthesiology. 1990; 73:568-70. [IDIS 271489] [PubMed 2393144]

388. Green D, Handley E. Erythropoietin for anemia in Jehovah’s Witnesses. Ann Intern Med. 1990; 113:720-1. [IDIS 273240] [PubMed 2221656]

389. Davis HP. Erythropoietin for patient refusing blood transfusion. Lancet. 1990; 2:384-5.

390. Kyger III ER, Blakestad BR. Management of Jehovah’s Witness patients. Ann Thorac Surg. 1990; 50:167. [PubMed 2369224]

391. Shepp DH, Agins BD, Farber BF. Erythropoietin for zidovudine-induced anemia. N Engl J Med. 1990; 323:1069-70. [IDIS 271975] [PubMed 2215568]

392. O’Connor BM, Shastri KA. Erythropoietin for zidovudine- induced anemia. N Engl J Med. 1990; 323:1070. [IDIS 271976] [PubMed 2215569]

393. Abels RI, Rudnick SA, Tsai HC. Erythropoietin for zidovudine-induced anemia. N Engl J Med. 1990; 323:1070. [IDIS 271976] [PubMed 2215569]

394. Baskin S, Lasker N. Erythropoietin-associated hypertension. N Engl J Med. 1990; 323:999. [IDIS 271827] [PubMed 2402271]

395. Eschbach JW. Erythropoietin-associated hypertension. N Engl J Med. 1990; 323:999-1000. [IDIS 271827] [PubMed 2402271]

396. Hori K, Onoyama K, Iseki K et al. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients. Clin Nephrol. 1990; 33:293-8. [PubMed 2376091]

397. Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHuEPO therapy in renal failure. Nephrol Dial Transplant. 1990; 5:232-4. [PubMed 2113653]

398. Abraham PA, Opsahl JA, Rachael KM et al. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol. 1990; 10:128-36. [PubMed 2349956]

399. Takeuchi M, Takasaki S, Shimada M et al. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. J Biol Chem. 1990; 265:12127-30. [PubMed 2373681]

400. Ortho Biotech Division. Procrit (epoetin alfa) prescribing information. Raritan, NJ; 2011 Jun.

401. Laupacis A for the Canadian Erythropoietin Study Group. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. Semin Nephrol. 1990; 10:11-9. [PubMed 2192412]

402. Abels R. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. Semin Nephrol. 1990; 10:20-5. [PubMed 2192413]

403. Nomura S, Osawa G, Karai M. Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin. Nephron. 1990; 55:210-3. [PubMed 2362636]

404. Oster W, Herrmann F, Gamm H et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990; 8:956-62. [PubMed 2189957]

405. Bunn HF. Recombinant erythropoietin therapy in cancer patients. J Clin Oncol. 1990; 8:949-51. [PubMed 2189955]

406. Goodnough LT. Erythropoietin therapy in autologous blood donors. Prog Clin Biol Res. 1990; 338:105-12. [PubMed 2189133]

407. Henry DH. Erythropoietin therapy in AIDS. Prog Clin Biol Res. 1990; 338:113-20. [PubMed 2189134]

408. Imai N, Kawamura A, Higuchi M et al. Physiochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem. 1990; 107:352- 9. [PubMed 2341370]

409. de Jong GMT, Kolsters G, Offerman JJG. Erythrocyte indices during treatment with human recombinant erythropoietin in dialysis patients. Nephrol Dial Transplant. 1990; 5:77- 8. [PubMed 2109289]

410. Watson AJ, Gimenez LF, Cotton S et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med. 1990; 89:432-5. [IDIS 273215] [PubMed 2220877]

411. Rogers S, Russell NH, Morgan AG. Effect of erythropoietin in patients with myeloma. Br Med J. 1990; 301:667.

412. Davis HP, Brown H. Epoetin alfa for anaemia of chronic leukaemia. Lancet. 1991; 1:47.

413. Taylor J, Mactier RA, Stewart WK et al. Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis. Br Med J. 1990; 301:476-7.

414. Nissenson AR, moderator. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med. 1991; 114:402-16. [IDIS 278524] [PubMed 1992884]

415. Thompson FL, Powers JS, Graber SE et al. Use of recombinant human erythropoietin to enhance autologous blood donation in a patient with multiple red cell allo-antibodies and the anemia of chronic disease. Am J Med. 1991; 90:398- 400. [IDIS 279301] [PubMed 2003523]

416. Kaupke CJ, Vaziri ND, Sampson JR et al. Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients. Int J Artif Organs. 1990; 13:218-22. [PubMed 2373550]

417. Piazza V, Galli F, Villa G et al. Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet. 1990; 2:255-6.

418. D’Andrea A, Fasman G, Wong G et al. Erythropoietin receptor: cloning strategy and structural features. Int J Cell Cloning. 1990; 8(Suppl 1):173-80. [PubMed 2157775]

419. Goodnough LT. Potential role of recombinant human erythropoietin in the peri-surgical setting. Int J Cell Cloning. 1990; 8:203-10. [PubMed 2182736]

420. Krantz SB, Sawyer ST, Sawada KI et al. Erythropoietin receptors and clinical use in rheumatoid arthritis. Int J Cell Cloning. 1990; 8(Suppl 1):181-98. [PubMed 2157776]

421. Lim VS, Flanigan MJ, Fangman J. Effect of hematocrit on solute removal during high efficiency hemodialysis. Kidney Int. 1990; 37:1557-62. [PubMed 2362408]

422. Van Wyck DB. The challenge of iron deficiency during r- HuEP therapy. Semin Dialysis. 1989; 2:135-6.

423. Teehan BP, Sigler MH, Brown JM et al. Hematologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc. 1989; 21(Suppl 2):63-6. [PubMed 2545019]

424. Lazarus JM, Hakim RM, Newell J. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis. 1990; 16:101-8. [PubMed 2382644]

425. Ballal SH, Domoto DT, Polack DC et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis. 1991; 17:29-33. [PubMed 1986567]

426. Abraham PA, Opsahl JA, Keshaviah PR et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis. 1990; 16:438-46. [PubMed 2239934]

427. Donnelly SM, Smith EKM. The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment. Am J Kidney Dis. 1990; 16:487- 90. [PubMed 2239943]

428. Donnelly SM, Ali MAM, Churchill DN. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum. Am J Kidney Dis. 1990; 16:447-51. [PubMed 2239935]

429. Groopman JE. Management of the hematologic complications of human immunodeficiency virus infection. Clin Infect Dis. 1990; 12:931-7.

430. Iki S, Yagisawa M, Ohbayashi Y et al. Adverse effect of erythropoietin in myeloproliferative disorders. Lancet. 1991; 337:187-8. [IDIS 276944] [PubMed 1670836]

431. Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administation to healthy subjects. Br J Clin Pharmacol. 1990; 29:709-13. [IDIS 268897] [PubMed 2378790]

432. Buemi M, Allegra A, Aloisi C et al. Different answer to recombinant human erythropoietin in anephric and non-anephric haemodialyzed patients. Nephron. 1990; 56:218-9. [PubMed 2243581]

433. Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clin Nephrol. 1990; 34:230-5. [PubMed 2268981]

434. Nonnast-Daniel B, Deschodt G, Brunkhorst R et al. Long- term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anemia. Nephrol Dial Transplant. 1990; 5:444-8. [PubMed 2122322]

435. Casati S, Castelnovo C, Campise M et al. Aluminum interference in the treatment of haemodialysis patients with recombinant human erythropoietin. Neprhol Dial Transplant. 1990; 5:441-3.

436. Hampl H, Riedel E, Scigalla P et al. Erythropoiesis and erythrocyte age distribution in hemodialysis patients undergoing erythropoietin therapy. Blood Purf. 1990; 8:117-25.

437. Nielsen OJ, Andersen LS, Ludwigsen E et al. Anaemia of rheumatoid arthritis: serum erythropoietin concentrations and red cell distribution width in relation to iron status. Ann Rheum Dis. 1990; 49:349-53. [PubMed 2383057]

438. Johnson WJ, McCarthy JT, Yanagihara T et al. Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int. 1990; 38:919-24. [PubMed 2266676]

439. Horina JH, Horn S, Silly H et al. Need for erythropoietin treatment in predialysis patients. Lancet. 1991; 337:562. [IDIS 278883] [PubMed 1671931]

440. D’Andrea AD, Zion LI. Erythropoietin receptor: subunit structure and activities. J Clin Invest. 1990; 86:681- 7. [PubMed 2168441]

441. Depner TA, Rizwan S, James JA. Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis. ASAIO Trans. 1990; 36:23-5.

442. Besarab A, Medina F, Musial E et al. Recombinant human erythropoietin does not increase clotting in vascular accesses. ASAIO Trans. 1990; 36:749-53.

443. Schwartz AB, Kelch B, Terzian L et al. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. ASAIO Trans. 1990; 36:691-6.

444. Mitsuyasu RT. Hematopoietic growth factors in the treatment of patients with HIV infection. Biotherapy. 1990; 2:173-81. [PubMed 1698092]

445. McMahon FG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990; 76:1718-22. [IDIS 275267] [PubMed 2224121]

446. Grimm G, Stockenhuber F, Schneeweiss B et al. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int. 1990; 38:480-6. [PubMed 2232491]

447. Fritschka E, Neumayer HH, Thiede HM et al. Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis. Br J Clin Pharmacol. 1990; 30:135S-8S. [IDIS 275240] [PubMed 2176518]

448. Montini G, Zacchello G, Baraldi E et al. Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr. 1990; 117:556-60. [IDIS 272807] [PubMed 2213378]

449. Fandrey J, Seydel FP, Siegers CP et al. Role of cytochrome P450 in the control of the production of erythropoietin. Life Sci. 1990; 47:127-34. [PubMed 2167416]

450. Salmonson T, Danielson BG, Grahen A et al. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J Int Med. 1990; 228:53-7.

451. Boissel JP, Bunmn HF. Erythropoietin structure-function relationships. Prog Clin Biol Res. 1990; 352:227-32. [PubMed 2402516]

452. Anon. r-HuEPO treatment IND program interim data analysis. Ortho Biotech r-HuEPO Treatment IND Update. 1991 (Spring):2-3.

453. Erslev AJ. Erythropoietin. N Engl J Med. 1991; 324:1339-44. [IDIS 280320] [PubMed 2017231]

454. Steinberg MH. Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med. 1991; 324:1369- 70. [IDIS 280325] [PubMed 1759999]

455. Digenis GE, Yatzidis H. Recombinant human erythropoietin and peritoneal dialysis. Invest J Artif Organs. 1990; 13:344-6.

456. Imai N, Higuchi M, Kawamura A et al. Physiochemical and biological characterization of asialoerythropoietin suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem. 1990; 194:457-62. [PubMed 2269277]

457. Taylor JE, Henderson IS, Mactier RA et al. Effects of withdrawing erythropoietin. BMJ. 1991; 302:272-3. [IDIS 277793] [PubMed 1998794]

458. DaCosta NA, Hultin MB. Effective therapy of human immunodeficiency virus-associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin. Am J Hematol. 1991; 36:71-2. [PubMed 1984688]

459. Mito M, Takahashi M, Suda T et al. Thrombocytosis and erythropoietin-unresponsive anemia in patients with Castleman’s disease. Am J Hematol. 1991; 36:77-8. [PubMed 1984689]

460. Stebler C, Tichelli A, Dazzi H et al. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol. 1990; 18:1204-8. [PubMed 2226680]

461. Spivak JL. Application of recombinant human erythropoietin in oncology. Cancer Invest. 1990; 8:301- 2. [PubMed 2400953]

462. Takashina N, Kondon H, Kashwazaki S. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. J Rheumatol. 1990; 17:885-7. [PubMed 2213753]

463. Koestner JA, Nelson LD, Morris JA Jr et al. Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah’s Witness refusing transfusion of blood products: case report. J Trauma. 1990; 30:1406-8. [PubMed 2231810]

464. Dessypris EN, Krantz SB. Erythropoietin regulation of erythropoiesis and clinical use. Adv Pharmacol. 1990; 21:127-47. [PubMed 2265125]

465. Shannon KM, Mentzer WC, Abels RI et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J Pediatr. 1991; 118:949-55. [IDIS 283843] [PubMed 2040933]

466. Macdougall IC, Roberts DE, Coles GA et al. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991; 20:99-113. [PubMed 2029809]

467. Ortho Biotech. Product information form for American Hospital Formulary Service on Eprex (epoetin alfa). Raritan, NJ; 1990 Jun.

468. Wagner JC. Abuse of drugs used to enhance athletic performance. Am J Hosp Pharm. 1989; 46:2059-67. [PubMed 2683762]

469. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. Adv Intern Med. 1991; 36:399-424. [PubMed 1673818]

470. Steinberg H. Erythropoietin and visual hallucinations. N Engl J Med. 1991; 325:285. [IDIS 283922] [PubMed 2057032]

471. Stead RB. Erythropoietin and visual hallucinations. N Engl J Med. 1991; 325:285.

472. Fisher LM. Stamina-building drug linked to athletes’ deaths. NY Times. 1991; (May 19):22.

473. Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med. 1991; 229:125-30. [IDIS 278414] [PubMed 1997637]

474. Cotes PM. Immunoreactive erythropoietin in serum. I. Evidence for validity of the assay method and the physiological relevance of estimates. Br J Haematol. 1982; 50:427-38. [PubMed 7066196]

475. Goldwasser E, Sherwood JB. Radioimmunoassay of erythropoietin. Br J Haematol. 1981; 48:359-63. [PubMed 7020745]

476. Cotes PM, Tam RC, Reed P et al. An immunological cross- reactant of erythropoietin in serum which may invalidate EPO radioimmunoassay. Br J Haematol. 1989; 73:25-8.

477. Cotes PM, Dore CJ, Yin JA et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med. 1986; 315:283-7. [PubMed 3724821]

478. Ortho Biotech. Procrit (epoetin alfa) practical guide. Raritan, NJ; 1991 Feb.

479. Keintsch-Engel R, Hallermayer K, Dessauer A. Methods for measuring erythropoietin and erythropoietin antibodies using ELISA technique. Contrib Nephrol. 1989; 76:100-5. [PubMed 2684514]

480. Kromer G, Solf A, Ehmer B et al. Single dose pharmacokinetics of recombinant human erythropoietin comparing intravenous, subcutaneous and intraperitoneal administration in IPD patients. Kidney Int. 1990; 37:331.

481. Emmanouel DS, Goldwasser E, Katz AI. Metabolism of pure human erythropoietin in the rat. Am J Physiol. 1984; 247(1 Part 2):F168-76.

482. Fu JS, Lertora JJ, Brookins J et al. Pharmacokinetics of erythropoietin in intact and anephric dogs. J Lab Clin Med. 1988; 111:669-76. [PubMed 3373111]

483. Egrie JC, Cotes PM, Lane J et al. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods. 1987; 99:235-41. [PubMed 3584994]

484. Offner G, Hoyer PF, Latta K et al. One year’s experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis. Pediatr Nephrol. 1990; 4:498-500. [PubMed 2242315]

485. Pascual J, Teruel JL, Ortu˜no J. Hypertensive effect of erythropoietin. Ann Intern Med. 1991; 114:1063.

486. Maxwell AP, Douglas JF, Afrasiabi M et al. Erythropoietin pharmacokinetics and red cell metabolism in haemodialysis patients. Nephrol Dial Transplant. 1989; 4:476.

487. Wikström B, Salmonson T, Grahnén A et al. Pharmacokinetics of recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1988; 3:503.

488. Valderrábano V. Adverse effects of recombinant human erythropoietin in the treatment of anaemia in chronic renal failure. Nephrol Dial Transplant. 1988; 3:503.

489. Aronoff GR, Duff DR, Sloan RS et al. The treatment of anemia with low-dose recombinant human erythropoietin. Am J Nephrol. 1990; 10(Suppl 2):40-3. [PubMed 2260617]

490. Ward HJ. Implications of recombinant erythropoietin therapy for renal transplantation. Am J Nephrol. 1990; 10(Suppl 2):44-52. [PubMed 2260618]

491. Corbo DC, Suddith RL, Sharma B et al. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent. Am J Hosp Pharm. 1992; 49:1455-8. [PubMed 1529989]

492. Goldwasser E, Kung CKH, Eliason J. On the mechanism of erythropoietin-induced differentiation. XIII. The role of sialic acid in erythropoietin action. J Biol Chem. 1974; 249:4202-6. [PubMed 4368980]

493. DeMarchi S, Cecchin E, Villalta D et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med. 1992; 326:969-74. [IDIS 294263] [PubMed 1545849]

494. Wognum AW, Lansdorp PM, Eaves AC et al. An enzyme-linked immunosorbent assay for erythropoietin using monoclonal antibodies, tetrameric immune complexes, and substrate amplification. Blood. 1989; 74:622-8. [PubMed 2473803]

495. Miles SA, Mitsuyasu RT, Moreno J et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 1991; 77:2109-2117. [IDIS 281893] [PubMed 1709368]

496. Burroughs Wellcome Co. Retrovir (zidovudine) capsules and syrup prescribing information. Research Triangle Park, NC; 1990 May.

497. Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989; 37:408-50. [IDIS 257966] [PubMed 2661194]

498. Cohen H, Williams I, Matthey F et al. Reversible zidovudine-induced pure red-cell aplasia. AIDS. 1989; 3:177-8. [PubMed 2496734]

499. Gelmon K, Montaner JS, Fanning M et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the multicenter Canadian azidothymidine trial. AIDS. 1989; 3:555-61. [PubMed 2528969]

500. Mir N, Costello C. Zidovudine and bone marrow. Lancet. 1988; 2:1195-6. [IDIS 248144] [PubMed 2903403]

501. Smith DA, Perry PJ. The efficacy of ergogenic agents in athletic competition. Part II: other performance-enhancing agents. Ann Pharmacother. 1992; 26:653-9. [IDIS 296425] [PubMed 1591427]

502. Carey J, Jackson B, Wallace M et al. The effect of R-HU erythropoietin on HIV p24 antigen expression in anemic zidovudine treated AIDS patients. Int Conf AIDS. 1990; 6:195.

503. Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs; proposed addition of “geriatric use” subsection in the labeling (Docket No. 89N-0474). Fed Regist. 1990; 55:46134-7.

504. National Collegiate Athletic Association. NCAA banned- drug classes, 1992-93 (Bylaw 31.2.3.1: Banned Drugs). Overland Park, KS.

505. Abraham PA, St. Peter WL, Redic-Kill KA et al. Controversies in determination of epoetin (recombinant human erythropoietin) dosages. Clin Pharmacokinet. 1992; 22:409-15. [PubMed 1587054]

506. Macdougall IC, Jones JM, Robinson MI et al. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol. 1991; 88:152-6. [PubMed 2040177]

507. Van der Wouw PA, Van Leeuwen R, Van Oers RHJ et al. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. Br J Haematol. 1991; 78:319-24. [PubMed 1714756]

508. United States Olympic Committee Division of Sports Medicine. Guide to banned medications. US Olympic Committee; 1990: 1 Nov.

509. Krantz SP. Erythropoietin. Blood. 1991; 77:419-34. [PubMed 1991159]

510. Reviewers’ comments (personal observations); 1992 Aug.

511. Graber SE, Krantz SB. Erythropoietin: biology and clinical use. Hematol/Oncol Clin NA. 1989; 3:369-400.

512. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood. 1988; 71:524-7. [PubMed 3337914]

513. Kazal LA, Erslev AJ. The measurement of erythropoietin. Ann Clin Lab Sci. 1975; 5:91-7. [PubMed 1092249]

514. Goldwasser E, Eliason JF, Sikkema D. An assay for erythropoietin in vitro at the milliunit level. Endocrinology. 1975; 97:315-23. [PubMed 239844]

515. Appelbaum FR. The clinical use of hematopoietic growth factors. Semin Hematol. 1989; 26(3 Suppl 3):7-14. [PubMed 2477905]

516. Koury ST, Bondurant MC, Koury MJ et al. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood. . 1991; 77:2497-503. [PubMed 2039831]

517. Balfour HH Jr, Abels R. Recombinant human erythropoietin (r-HuEPO) treatment IND (T-IND) for anemia in persons with AIDS not receiving zidovudine (AZT). VIII International Conference on AIDS/III STD World Congress. Amsterdam; 1992 July 19-24:PoB 3728.

518. Amgen, Thousand Oaks, CA: Personal communication.

519. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97 414). Rockville, MD; 2009 Jul 28. From FDA website. Accessed 2009 Aug 17.

520. Anderson KE, Goeger DE. Erythropoietin for porphyria cutanea tarda in renal failure. Clin Pharmacol Ther. 1992; 51:138.

521. Teehan BP, Sigler MH, Brown JM et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc. 1989; 21(Suppl 2):63-6. [PubMed 2545019]

522. Benz R, Buckalew V, Hatch F et al. Renal function in predialysis patients receiving recombinant human erythropoietin (r-HuEPO) therapy for the anemia of chronic renal insufficiency (CRI). Interim results of a multicenter trial. Clin Res. 1992; 40:179A.

523. Henry DH, Jemsek JG, Levin AS et al. Recombinant human erythropoietin and the treatment of anemia in patients with AIDS or advanced ARC not receiving ZDV. J Acquir Immune Defic Syndr. 1992; 5:847- 52. [PubMed 1517970]

524. Abels RI, Larholt KM, Krantz KD et al. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In: Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing symposium. Murphy MJ Jr, ed. AlphaMed Press: Dayton, OH; 1991.

525. Abels RI, Rudnick SA. Erythropoietin: evolving clinical applications. Exp Hematol. 1991; 19:842-50. [PubMed 1868899]

526. Nonoguchi H, Abe K, Komatsu F. Recombinant human erythropoietin for autologous blood donation. Lancet. 1992; 339:1483. [IDIS 298200] [PubMed 1351158]

527. Platanias LC, Miller CB, Mick R et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991; 9:2021-6. [PubMed 1941061]

528. Henry DH. Erythropoietin in the treatment of anemia associated with cisplatin chemotherapy. Biother Cancer. 1990; 3:1,6,7.

529. Oster W, Herrmann F, Mertelsmann R. Erythropoietin for the treatment of patients with anemia of malignancy. In: Hematopoietic growth factors in clinical applications. Mertelsmann R and Herrmann F, eds. New York: Marcel Dekker; 1990:141-8.

530. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992; 19(3 Suppl 8):29-35. [PubMed 1615337]

531. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood. 1991; 78:1658-63. [IDIS 289472] [PubMed 1912554]

532. Schouten HC, Vellenga E, van Rhenen DJ et al. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia. 1991; 5:432-6. [PubMed 2033964]

533. Kurzrock R, Talpaz M, Estey E et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991; 5:985-90. [PubMed 1961041]

534. Holley JL, Nolan TA, Piraino B. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease. Clin Nephrol. 1992; 37:145-7. [PubMed 1563119]

535. Berdel WE, Oberberg D, Reufi B et al. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol. 1991; 63:5-8. [PubMed 1878424]

536. James RD, Wilkinson PM, Belli F et al. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta Haematol. 1992; 87(Suppl 1):12-5. [PubMed 1574960]

537. de Campos ES, Radford JA, Steward WP et al. The effect of RHU erythropoietin (EPO) on levels of hemoglobin and number of red cell and platelet transfusions during intensive chemotherapy for small cell lung carcinoma (SCLC). Br J Cancer. 1991; 63(Suppl 13):9. [PubMed 1989670]

538. Henry DH, Staddon AP, Mason BA et al. Prevention of anemia in breast cancer patients receiving adriamycin-containing chemotherapy with recombinant human erythropoietin (r-HuEPO). Blood. 1991; 78(Suppl 1):92A.

539. Oblon D, Johnson T, Miller-McCauley V et al. Recombinant human erythropoietin (r-HuEPO) allows autologous blood donation by abrogating the anemia associated with intensive neoadjuvant chemotherapy. Proc Am Soc Clin Oncol. 1992; 11:404.

540. Schollmeyer P, Lubrich-Birkner I, Steinhauer HB. Effect of recombinant human erythropoietin on anemia and dialysis: efficiency in patients undergoing CAPD. Contrib Nephrol. 1990; 87:95-104. [PubMed 2093545]

541. Steinhauer HB, Lubrich-Birkner I, Dreyling KW et al. Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Invest. 1991; 21:47-52. [PubMed 1907554]

542. Steinhauer HB, Lubrich-Birkner I, Schollmeyer P. Effect of human recombinant erythropoietin on dialysis efficiency in CAPD. Contrib Nephrol. 1991; 89:214-23. [PubMed 1909946]

543. Korbet SM, Vonesh EF, Firanked CA. The effect of hematocrit on peritoneal transport. Am J Kidney Dis. 1991; 18:573-8. [PubMed 1951337]

544. Taylor JE, MacTier RA, Henderson IS et al. Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin. Perit Dial Int. 1992; 12:221-6. [PubMed 1586685]

545. Hutchison AJ, Ofsthun NJ, Howarth D et al. The effect of hemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory peritoneal dialysis. Perit Dial Int. 1992 12:230-3.

546. Granolleras C, Branger B, Beau MC et al. Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol. 1989; 76:143-8. [PubMed 2684516]

547. Shannon KM. Anemia of prematurity: progress and prospects. Am J Pediatr Hematol/Oncol. 1990; 12:14-20.

548. Shannon KM. Recombinant erythropoietin in pediatrics: a clinical perspective. Pediatr Ann. 1990; 19:197-206. [PubMed 2181391]

549. Rigden SPA, Montini G, Morris M et al. Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatr Nephrol. 1990; 4:618-22. [PubMed 2088464]

550. Carnielli V, Montini G, Da Riol R et al. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Pediatr. 1992; 121:98-102. [IDIS 299962] [PubMed 1625101]

551. Becker CE, MacGregor RR, Walker KS et al. Fatal anaphylaxis after intramuscular iron-dextran. Ann Intern Med. 1966; 65:745-8. [PubMed 5926393]

552. Hart GD, Soots M. An anaphylactic reaction complicating total dose infusion therapy of iron deficiency. Appl Ther. 1969; 11:645-6. [PubMed 5364340]

553. Jacobs J. Death due to iron parenterally. South Med J. 1969; 62:216. [PubMed 5304742]

554. Henry DH, Beall GN, Benson CA et al. Recombinant human erythropoeitin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med. 1992; 117:739-48. [IDIS 304312] [PubMed 1416576]

555. Ohls RK, Wirkus PE, Christensen RD. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease. Pediatrics. 1992; 90:678-80. [IDIS 305971] [PubMed 1408538]

556. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. [IDIS 175725] [PubMed 6889041]

557. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12:10-1. [PubMed 7188569]

558. Centers for Disease Control. Neonatal deaths associated with use of benzyl alcohol. MMWR Morb Mortal Wkly Rep. 1982; 31:290-1. [IDIS 150868] [PubMed 6810084]

559. Gershanik J, Boecler B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982; 307:1384-8. [IDIS 160823] [PubMed 7133084]

560. Menon P, Thach BT, Smith CH et al. Benzyl alcohol toxicity in a neonatal intensive care unit: incidence, symptomatology, and mortality. Am J Perinatol. 1984; 1:288-92. [PubMed 6440575]

561. Anderson CW, Ng KJ, Andresen B et al. Benzyl alcohol poisoning in a premature newborn infant. Am J Obstet Gynecol. 1984; 148:344-6. [IDIS 181207] [PubMed 6695984]

562. Maier RF, Obladen M, Scigalla P et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med. 1994; 330:1173-8. [IDIS 328584] [PubMed 8139627]

563. Strauss RG. Erythropoietin and neonatal anemia. N Engl J Med. 1994; 330:1227-8. [IDIS 328585] [PubMed 8139633]

564. Meyer MP, Meyer JH, Commerford A et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study. Pediatrics. 1994; 93:918-23. [IDIS 330943] [PubMed 8190577]

565. National Kidney Foundation Study Group: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997; 30(suppl 3):S192-S237.

566. Allegra V, Mengossi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis critieria and of three different iron treatments. Nephron. 1991; 57:175-82. [PubMed 1902285]

567. Besarab A, Frinak S, Yee S. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999; 10:2029-43. [PubMed 10477157]

568. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with epoetin alfa. Kidney Int. 1996; 50:1694-9. [PubMed 8914038]

569. Macdougall IC, Cavill I, Hulme B et al. Detection of functional iron deficiency during epoetin alfa treatment: a new approach. BMJ. 1992; 304:225-6. [IDIS 291424] [PubMed 1739797]

570. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis. 1992; 3:71-5.

571. Brown SL, Amgen. Dear health care provider letter regarding extrinsic bacterial contamination of Epogen. Thousand Oaks, CA; 2000 Mar 24. From FDA web site.

572. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol. 2004;

573. Nissenson AR, Swan SK, Lindberg JS et al. Novel erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-HuEPO when administered once weekly. Paper presented at 33rd American Society of Nephrology annual meeting. Toronto, Canada: 2000 Oct. Abstract 1326.

574. Vanrenterghem P, Barany P, Mann J, on behalf of the European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hgb) in ESRD patients when administered once weekly or once every other week. Paper presented at 32nd American Society of Nephrology annual meeting. Miami, FL: 1999 Nov. Abstract 1365.

575. Amgen Inc. Darbepoetin alfa: Summary of clinical publications. Thousand Oaks, CA; undated.

576. Graf H, Lacombe JL, Braun J et al. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients. Paper presented at 33rd American Society of Nephrology annual meeting. Toronto, Canada: 2000 Oct. Abstract.

577. Anon. Darbepoetin (Aranesp)—a long-acting erythropoietin. Med Lett Drugs Ther. 2001; 43:109-10. [PubMed 11740411]

578. Brunkhorst R, Bommer J, Braun J et al for the German Aranesp Study Group. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant. 2004; 19:1224-30.

579. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 2003 Feb;18(2):362-9.

580. Vanrenterghem Y, Barany P, Mann JF et al for the European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62:2167-75.

581. Brenner R. Dear health care professional letter regarding pure red cell aplasia with Epogen. Thoursand Oaks, CA: Amgen; 2005 Nov. Available from website. Accessed 2006 Jun 2.

582. Kamin M. Dear health care professional letter regarding pure red cell aplasia with Procrit. Raritan, NJ: Ortho Biotech; 2005 Nov. Available from website. Accessed 2006 Jun 2.

583. Kamin M. Dear health care professional letter regarding treatment of chemotherapy-induced anemia in children with Procrit. Raritan, NJ: Ortho Biotech; 2006 Apr.

584. Food and Drug Administration. Information for healthcare professionals on erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Rockville, MD; November 16, 2006. From FDA website.

585. Singh KA, Szczech L, Tang KL et al for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98. [PubMed 17108343]

586. Remuzzi G, Ingelfinger JR. Correction of anemia — payoffs and problems. N Engl J Med. 355; 20:2144-6.

587. Drüeke TB, Locatelli F, Clyne N et al for the CREATE Investigators.. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.

588. Food and Drug Administration. FDA public health advisory regarding epoetin alfa (marketed as Procrit, Epogen) and darbepoetin alfa (marketed as Aranesp). Rockville, MD; November 16, 2006. From FDA website.

589. Food and Drug Administration. FDA public health advisory regarding erythropoiesis-stimulating agents (ESAs): epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). Rockville, MD; March 9, 2007. From FDA website.

590. Food and Drug Administration. Information for healthcare professionals on erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Rockville, MD; November 16, 2006 [updated 2/16/2007 and 3/9/2007]. From FDA website.

591. Harper S. Dear health care professional letter regarding Aranesp (darbepoetin alfa). Thousand Oaks, CA: Amgen; 2007 Jan 26.

593. Fernandes M, Sawa H, Bellini G. Haemoglobin concentrations in chronic kidney disease.Lancet. 2007; 369(Feb 3):365. Letter. [PubMed 17276763]

594. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369(Feb 3):381-8. [PubMed 17276778]

595. Strippoli GFM, Tognoni G, Navaneethan SD et al. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007; 369(Feb 3):346.-50. [PubMed 17276756]

596. Renal Physicians Association. Nation’s kidney doctors express concern over U.S. Food and Drug Administration’s health advisory on anemia drugs. Rockville, MD; 2007 Mar 12. Press release from website.

597. Amgen. Aranesp (darbepoetin alfa) for injection prescribing information. Thousand Oaks, CA; 2009 Apr.

598. Ortho Biotech. Procrit (epoetin alfa) information for patients and their caregivers. Raritan, NJ; 2007 Mar.

599. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(Oct 18):1255-60.

600. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10. Study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. Available from website. Accessed 2007 Apr 7.

601. Ortho Biotech, Raritan, NJ: Personal communication.

602. Food and Drug Administration. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]; FDA alert [updated 11/8/2007]. From FDA website.

603. Food and Drug Administration. FDA public health advisory regarding erythropoiesis-stimulating agents (ESAs): Epoetin alfa (marketed as Procrit and Epogen), Darbepoetin alfa (marketed as Aranesp). Rockville, MD; November 8, 2007. From FDA website.

604. Food and Drug Administration. Questions and answers for erythropoeisis-stimulating agents (ESAs) labeling changes. Rockville, MD; November 8, 2007. From FDA website.

605. Smith RE, Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, mulitcenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008; 26:1040-50. [PubMed 18227526]

606. Thomas G, Ali S, Hoebers FJP et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008; 108:317-25 [PubMed 18037478]

607. Harper SE, Tendler C. Dear health care professional letter: Additional trials showing increased mortality and/or tumor progression with Epogen/Procrit and Aranesp. Rockville, MD: US Food and Drug Administration; 2008 Mar 7. From FDA website.

608. Food and Drug Administration. Follow Up to the January 3, 2008 Communication About an Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). Rockville, MD; Oct 1, 2008. From FDA website.

609. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23:5960-72.

610. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584-90. [PubMed 9718377]

611. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies in 9353 patients.J Natl Cancer Inst. 2006; 98:708-14. [PubMed 16705125]

612. D’Ambra MN, Gray RJ, Hillman R et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997; 64:1686-93.

613. National Kidney Foundation Dialysis Outcomes Quality Initiative. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007; 50:471-530. [PubMed 17720528]

614. Food and Drug Administration. Communication about an ongoing safety review: erythropoiesis-stimulating agents (ESAs) Epoetin alfa marketed as Procrit, Epogen darbepoetin alfa (marketed as Aranesp). Rockville, MD; Jan 3, 2008. From FDA website.

615. Amgen. Epogen (epoetin alfa) medication guide. Thousand Oaks, CA; 2011 June.

616. Harper SE, Schaible TF. Dear health care professional letter: Reports of antibody-mediated pure red cell aplasia and transfusion-dependent anemia in patients with hepatitis C virus (HCV) infection treated with ribavirin and interferon or pegylated interferon and an erythropoiesis-stimulating agent (ESA) concurrently. Amgen and Centocor Ortho Biotech Services; 2009 April 8.

617. Stravitz RT, Chung H, Sterling RK et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol. 2005; 100:1415-9. [PubMed 15929778]

618. Food and Drug Administration. Early communication about an ongoing safety review of epoetin alfa. Rockville, MD; Sep 26, 2008. From FDA website.

619. Food and Drug Administration. Drug Safety Communication: erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp. Rockville, MD; Feb 16, 2010. From FDA website.

620. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019-32. [PubMed 19880844]

621. American Society of Hematology. Information on how the new ESA REMS program will affect MDS patients. Washington, DC; 2010 Mar 11. Press release. From website. Accessed 2010 Jun 18.

622. Unger EF, Thompson AM, Blank MJ et al. Erythropoiesis-stimulating agents—time for a reevaluation. N Engl J Med. 2010 Jan 21; 362:189-92.

624. Food and Drug Administration. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease . Rockville, MD; Jun 24, 2011. From FDA website.

625. Besarab A, Goodkin DA, Nissenson AR et al. The normal hematocrit study--follow-up. N Engl J Med. 2008; 358:433-4. [PubMed 18216370]

HID. Trissel LA. Handbook on injectable drugs. 16th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2011:600-1.

Hide
(web4)